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ABSTRACT

Infection by Human Immunodeficiency Virus (HIV) is a multifactor disease
process in which the patient must confront an array of physiological, sociocultural, economic, and psychological stressors that have the collective
potential for triggering major stress responses and psychological dysfunction.
People's reactions to and the outcomes of traumatic events are mediated by
their subjective style of coping. Coping is defined as a person's "constantly
changing cognitive and behavioral efforts to manage specific external and
internal demands that are appraised as taxing or exceeding the resources of a
person". Coping, an important psychological construct has been shown to
affect outcomes such as disease progression and quality of life in HIV infected
patients. But the subjective styles of coping that patients use to cope with HIV
have rarely been assessed as predictors of medication adherence. This study
aims at determining the role of coping styles as determined by the "Ways of
coping questionnaire" modified by Dunkel-Schetter et al. to suit their study of
cancer patients as

predictors of medication adherence in patients infected

with HIV. The five dimensions of coping identified by Dunkel-Schetter et al.
were the first to be identified with a large sample of cancer patients and may
be representative of the universal dimensions of coping. This study is the first
to utilize the dimensions of coping as described by Dunkel-Schetter et al. to
predict adherence in HIV patients. The few studies on coping styles and
adherence as an outcome use varied coping scales to assess coping like the
Billings and Moos coping inventory and original Ways of coping
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questionnaire. Their results have shown that poor copmg strategies like
avoidance coping were associated with non-adherence.
Methods: The sample for the study consisted of 145 patients who were
currently prescribed medication for HIV. The medication adherence shown by
patients with anti-retroviral drugs and protease-inhibitor drugs was assessed
separately. A total of 137 patients were on anti-retroviral drugs, while 77
patients were on protease-inhibitor drugs. Medication adherence was
determined by using the "percentage of doses missed in the past three months
and "Medication Adherence Scale. Coping strategies used by the patients
were assessed by the "Ways of coping questionnaire" developed by Lazarus
and colleagues and later modified by Dunkel-Schetter et al. to suit their study
of cancer patients. The scale comprised of five coping sub-scales: seeking
social support, distancing, focusing on positive, behavioral escape avoidance
and cognitive escape avoidance and assessed the frequency of use of each
coping style. Several demographic variables as well as clinical variables,
which are known to affect medication adherence, were examined. Logistic
Regression analyses were used to determine whether the coping strategies
were predictive of medication adherence controlling for the confounding
factors .
Results: In agreement with previous research that shows that poor coping was
associated with non-adherence, for the patients prescribed antiretroviral
medications, behavioral escape avoidance was found to be significantly and
inversely associated with adherence. Seeking social support, distancing,

focusing on positive and cognitive escape avoidance were not found to be
significantly associated with medication adherence.
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INTRODUCTION
Acquired Immunodeficiency Syndrome (AIDS) is a devastating disease facing
humankind. Since the epidemic started in 1981, more than 60 million people
worldwide have been infected with the Human Immunodeficiency virus (HIV),
which causes AIDS. Worldwide, AIDS is the fourth leading cause of death. In the
United States, approximately 1 million people are either infected with HIV or
have AIDS. In the United States, the incidence of HIV is approximately 40
thousand cases every year. Thus, HIV infection and AIDS are significant public
health problems and challenges. (1)
Until quite recently, the disease was considered to carry an almost certain
debilitating, downward course leading to early death from opportunistic
infections. A variety of medications were used to treat HIV related diseases, and
some such as Zidovudine could temporarily suppress levels of HIV responsible
for immune compromise. However the treatment only produced transient benefits
because the circulating HIV remained in enormous quantity and the virus has a
rapid error prone replication cycle that allows it to quickly evolve resistance to
any single drug. The nature of medical care changed dramatically in 1996 with the
development and wide use of treatment regimen that added a new class of antiretroviral medication called protease inhibitors in combination with other antiretroviral medications (2). Highly Active Anti-retroviral Therapy (HAART),
usually a protease inhibitor combined with at least two other drugs, controls the
viral replication by targeting specific viral enzymes. There are currently two
distinct groups of anti HIV drugs that are targeted at different viral enzymes.
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These are reverse -transcriptase inhibitors and protease inhibitors (3). HAART
has enormous potential to delay disease progression and death (4). HAART is
designed to suppress HIV viral replication, which results in increases in CD4 cell
count, improved immune function, delayed clinical progression, and prolonged
survival (5,6). Successful treatment of HIV with HAART requires that patient
maintain nearly perfect adherence to the prescribed regimen. Adherence, often
used interchangeably with compliance, is "the act, or quality of being consistent
with administration of prescribed medication". Non- adherence may mean not
taking medication at all, taking reduced amounts, not taking doses at prescribed
frequencies or intervals or not matching medication to the food requirements (7).
A] Important of Adherence

Adherence to HAART is the single most important factor for achieving
maximum and durable HIV plasma viral load suppression. Several studies have
demonstrated that lapses in anti-retroviral adherence lower the likelihood of
suppressing viral loads below detectable limit (8).

Non-adherence leads to

increased mortality and morbidity. A study by Hoggs et al. (9) reported a 16% rise
in mortality for every 10% drop in adherence.
Strict adherence to HAART is imperative because the therapy is
"unforgiving" in two respects. First, m non-adherent patients, resistant viral
strains develop because of high rates of viral mutation and the short half-life of
the drugs (10). Condra et al. (11,12,13) reported that resistance might develop
after missing as little as one dose in five. The genetic mutations that result in drug
resistance often confer resistance to an entire class of protease inhibitors or non-
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nucleosides. Thus, in failing one regimen, a non-adherent patient may severely
limit future antiviral options (10). Secondly, the level of adherence that must be
achieved and maintained for maximal effectiveness exceeds that needed for
effective therapy in many other chronic conditions. With HAART, patients must
maintain near- perfect adherence to maintain an undetectable viral load (10). A
study by Paterson et al. reported only 50% patients with 80%-90% adherence
achieved undetectable viral loads. Patients required better than 95% adherence to
achieve highest rate of undetectable viral load ( 14). The development of resistant
strains is also a significant public health concern because of the possibility of
transferring the resistant strain to others. Evidence was reported documenting the
sexual transmission of virus resistant to all known classes of anti-retroviral drugs
including protease inhibitors (15). In a prospective study of 93 patients, self
reported adherence was independently associated with undetectable seminal HIV
RNA level after six months of therapy (16).
One hundred percent adherence to HAART is not easy to achieve. Studies of
HIV/AIDS patients have reported low adherence rates. In a cross sectional study
by Mostashari et al (17), involving 102 HIV infected females, 62% females
reported taking all medications for >= 6 days a week, and were classified as
adherent. In an observational cohort study called the ATHENA study (18),
adherence to HAART was obtained by self-report and validated by blood assays.
Of the 224 patients, 53. l % reported taking all the medications on time, and also
followed dietary requirements for the last week. The rest reported missing doses
or not taking them on time and were classified as non-adherent. In a study on 46
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patients with HN, Singh et al. (19) reviewing monthly prescription fill records
assessed adherence to antiretroviral therapy. All patients filling >=80% of their
medications were defined as being adherent. With this criteria, 63% patients were
adherent. In a study that of 180 patients randomized into either MEMS, diaries
and no surveillance groups, the adherence in the past four weeks was 80.6%, 92%
and 93% respectively (20). In a retrospective study of pharmacy claims data
regarding prescription fills to assess adherence to HIV medications, only 26%
patients had more than 80% adherence. Adherence was defined as proportion of
days on which drugs were taken during the first 365 days on therapy. The mean
adherence was 53% (21). Thus, the adherence has been found to be less than
adequate.
B] Assessment of adherence

A major problem in studying adherence is the lack of a standard measure (8).
There is no "gold standard" for measuring adherence. The four methods used
most commonly to measure adherence are self reported (questionnaire/ interview/
diary), pill counts, drug assay, and electronic monitoring.
Self Reported Questionnaires: It is the most common, inexpensive and simple

method of determining adherence (22). Advantages of this method include low
costs, easily obtainable results and flexibility to tailor the method to the language
and reading competency of the subjects (23). Patient self reports are often the only
available method. However, the validity of this measure is questionable. In
general, self- reports tend to overestimate adherence compared with other
methods of determining adherence, like pill counts or electronic monitoring.
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Recall bias is another concern (23). Among HIV-infected patients however, there
tends to be a strong correlation between self-reports and virologic outcomes.
Though this method may not be as accurate as desired, there may be reason to
believe that it is useful because patients reporting non-adherence are usually at
least as non-adherent as indicated by interview (24).

Pill Counts: Having a physician, nurse or other health care practitioner count pills
remaining in a bottle is another way to measure adherence (8). This method
involves a comparison of the medicine left in the bottle and the quantity that
should have been left if the medication had been taken. The advantage of this
method is that they are potentially affected less than the other methods by
subjective patient response (8). Adherence assessed by this method correlate
better with that measured from electronic bottle caps than does self-reported
adherence (25). However, this method had several limitations. Patients may forget
to bring their bottles to the clinic when instructed. It is very time-consuming.
Patients may empty the bottle or may take all the remaining pills before the visit
to the clinic (26).

Drug assay: Plasma and urinary blood levels provide useful objective assessment
of adherence (27). The accuracy of this method depends in part on the half-life of
the drug (26), which is the time required for the potency of the drug to fall to half
or to be eliminated from the body. This means that it depends on how soon the
drug reaches the systemic circulation so as to be detected in a drug assay. These
studies are very inconvenient and expensive. Some patients may object to having
their blood drawn, regarding this as unnecessary and intrusive. Also, patient-to-
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patient variability is a drawback (28). In addition, results may be confounded by
pharmacokinetic factors, such as poor drug absorption or drug -drug interactions,
which may mimic poor adherence (8).

Electronic monitoring: Bottles fitted with caps harboring electronic chips that
register each time a pill bottle is opened or closed constitute the most
sophisticated method currently available for measuring adherence. Two systems
are available: Medication Event Monitoring System (MEMS) and the eDEM
monitor (8). Data from the MEMS allows calculation of 1) the adherence rate, 2)
prescribed frequency, and 3) prescribed interval. This measure also does not
directly measure whether the patient took the medication; hence the accuracy of
this method is suspect (26).
C] Determinants of Adherence
Given the importance of adherence with medication regimen in the success of
HAART, most research in medication adherence in HIV infection has focused on
predictors of adherence and factors affecting adherence. These factors can be
classified as patient characteristics, clinical characteristics, treatment regimen
characteristics, clinician and clinician-patient relationship and psychological and
emotional characteristics.

Patient Characteristics: The literature on adherence strongly and consistently
demonstrates that adherence cannot be predicted solely on the basis of gender,
age, race or educational status (29). Factors that affect the initiation and adherence
to anti-retroviral therapies are knowledge and beliefs about the disease and
medication, social support, co-morbid conditions, substance abuse, cognitive
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impairment, depression and other mental illnesses (5). Thus adherence is may not
related to income, social class, occupation or educational background and nor can
it be accurately predicted by physicians (30). In a pilot study to test the effect of
behavioral medical management of adherence, self reported adherence in the past
four days improved from a mean of 80% to 98% in the group receiving behavioral
based intervention of education about the therapy, positive reinforcements and
encouragement, counseling and life style assessments (31). Thus knowledge about
therapy and positive reinforcement enhance adherence

Clinical Characteristics: After a critical literature review, Haynes (29)
commented that there are few associations between disease features and
adherence. The only exception being that when patients get better from any illness
they are less likely to adhere to treatment regimen (32,33,34).
Medications are more likely to be taken for short term, symptomatic illnesses,
where there is a more easily appreciated direct connection between medication
and therapeutic effect. (35).

Treatment regimen characteristics: It has been well documented that the
likelihood of adherence declines with an increase in the number of medications,
frequency of dosing, severity of side effects, and complexity and anticipated
duration of side effects. The more the regimen requires alterations or disruptions
in daily routines and lifestyle, the less likely will be excellent adherence (36).
Unfortunately, these negative characteristics are associated with the current,
complex

anti-retroviral

medication

regimen.

Combination

anti-retroviral

medication regimen involve large number of pills with varying dosing schedules,
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food requirements, lifestyle rearrangements and lifelong administration (5).
Furthermore, there are numerous side effects associated with the therapy. These
include nausea, vomiting, anemia, granulocytopenia, pancreatitis, peripheral
neuropathy, oral stomatitis, malaise, skin rash, and fever, to name a few (3).

Psychological and emotional characteristics:
a)

Mood status is an important predictor of adherence. A level of anxiety

either too high or too low may be related to non-adherence (37). Many cognitive,
psychosocial factors as well as well being and quality of life also have impact on
adherence.
b) Coping: The concept that susceptibility to, and infectious diseases may be
influenced by psychological factors has a very long history. The historical basis
for studying the relationship between psychological stress and the immune
response has been noted from centuries of clinical observations of individuals
who became sick following stressful situations. Infection by HN is a multifactor
disease process in which the patient must confront an array of physiological,
socio-cultural, economic, and psychological stressors that have the collective
potential for triggering major stress responses and psychological dysfunction (38).
Individuals suffering from a chronic medical condition face a variety of stressful
life circumstances involving a range of adaptation demands (39). Infection with
HIV raises a wide spectrum of concerns and fears among infected individuals.
Even before symptoms occur, those infected with HIV have concerns about the
future economic security, sexuality and disease transmission, rejection from
family, friends, lovers; and eventually ill health and death (40). Diagnosis of HIV
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is a traumatic event as it not only presents the possibility of death, but also raises
fears regarding changes in appearance, body functioning, role and self esteem
(41).

The uncertainty of the outcome of the infection can lead to anxiety.

Reaction of others to the patients' diagnosis constitutes a significant concern
(Ross and Rosser, 1988). In addition, individuals may not be able to conceal their
illness from significant others if their symptoms are severe. They may need to
take time off from work or stop working altogether. Such changes may lead to
cessation of employer sponsored health insurance benefits, social supports,
contact with acquaintances and income. The stresses of giving up work are
considerable, often leading to depression and lack of self-esteem (42).
Chronically ill patients must cope with the loss of independence, the threat of
disease progression, and in most cases, the challenge of modifying their behavior
to meet the demands of prescribed medication regimen. Patient adherence to a
prescribed regimen can involve a range of adaptive tasks including dietary
change, use of medication and change in physical activity (43).
People's reactions to traumatic events are mediated by their subjective style of
coping (44). For this study, the conceptualization of coping is based on the work
of Lazarus and his colleagues. In Lazarus and Folkman's transactional stress and
coping model, stressors themselves do not predict unfavorable outcomes, but
rather how one appraises and copes with them determine to some extent their
impact on one's health and well-being. Within this model, coping is defined as a
person's "constantly changing cognitive and behavioral efforts to manage specific
external and internal demands that are appraised as taxing or exceeding the
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resources of a person" (44). Thus, coping refers to an individual's cognitive and
behavioral efforts to manage specific situations that are appraised as stressful. The
reaction and outcome for a particular outcome will depend on the subjective
appraisal of the stressor and the coping style used.
Coping styles have been consistently related to mental health adjustments and
other health outcomes. Many studies have investigated the relationship between
styles of coping and subsequent health in HN. For example, Ironson et al. found
that reaction to the news that one was seropositive for HIV with denial was
associated prospectively at one-year follow-up with greater CD4 decline and
lower T cell proliferative response and with a greater likelihood of symptoms or
death after two years (45). Conversely, Blornkvist et al. found that 'active
optimistic coping' was negatively related to mortality over 1-7 years in a
hemophiliac cohort (46). A study by Goodkin et al. on eleven asymptomatic
HIV+ patients proved that passive coping styles were associated with lower total
lymphocyte count and thus may also be predictor of development of AIDS (47).
Thus considerably body of evidence suggests that psychological factors and
coping play an important role in progression of HIV infection, its morbidity and
morbidity. Many researchers have explored the effect of coping on many varied
outcomes, but not much work has been carried out to explore the association of
coping styles with medication adherence. Christensen et al (48). explored the
adherence behavior and coping style preferences among renal dialysis patients.
Adherence was predicted to be maximized in cases in which the patients'
preferred style of coping matched the type of treatment they received. Planful
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problem solving, a type of coping strategy was associated with more favorable
adherence (48). In a longitudinal observational study involving 46 HIV positive
patients, Singh et al. found that patients who were compliant with their
medications had significantly better adaptive coping (19). In another study
involving 123 HIV positive patients, Singh et al. reported that refill compliance
with antiretroviral medications was significantly associated with problem focused
coping (49). The limited studies on coping styles and adherence have been very
varied in the use of coping scales to determine coping styles. No study has
assessed the coping scales 'seeking social support', 'focusing on positive',
'distancing', 'behavioral escape avoidance', 'cognitive escape avoidance' as
predictors of adherence. Also, in the study by Singh et al. (19), the sample
comprised of only males. Coping needs to studies on a representative sample to
make the results generalizable.
Measurement of coping strategies includes standardized instruments, interviewing
protocols or observational techniques that assess the use of coping strategies to a
specific stressor (50). Many instruments have been developed to determine the
coping strategy used by people. The "ways of coping questionnaire" is one of the
standardized instruments that have been used extensively as a research instrument
in studies of the coping process. It has been derived from a cognitivephenomenological theory of stress and copmg developed by Lazarus and
colleagues (51). This measure consists of a series of predicates, each of which
portrays a coping thought or action that people sometimes engage in when under
stress. This instrument and its modifications have been used in many studies in a
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variety of settings. For example, Vitalinio et al. used the instrument to determine
coping as an index of illness behavior in panic disorders (52). This scale was
revised by Lazarus, Folkman, and Dunkel-Schetter to develop a questionnaire
with 51 items. This scale was again modified by Dunkel-Schetter, Feinstein,
Taylor and Flake (53) to suit their study on cancer patients. These were the first
coping patterns to be identified with a large and heterogeneous sample of cancer
patients and they are similar to those identified with a large sample of community
residents experiencing a variety of life stressors. It appears that they may be
representative of universal dimensions of coping. The five factors developed as a
result of factor loadings were: seeking social support, distancing, focusing on
positive, cognitive escape avoidance, and behavioral escape avoidance. In this
study, these factors will be assessed as a predictor of medication adherence. There
is great variability in the assessment of coping. This study shall add to the
understanding of coping styles used by the HN patients and also to the adherence
behavior and predictors of the same.
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METHODOLOGY

A. Study Setting and Sample
The sample consisted of 145 patients who were currently prescribed medication
for HIV. The eligibility criteria for this study included age between 18 and 74
years, current use of approved antiretroviral medications or protease inhibitors, or
use of approved medication for HIV- related complications and prophylaxis of
opportunistic infections (for example, trimethoprim, sulfamethoxazole used in the
prophylaxis of Pneumocystic carnii pneumonia), ability to read English, and a
positive HIV status.
The purpose of the original study was to develop measures of stages of change for
medication adherence. The study was funded by the National Institute of Health
(NIH) and was conducted by Dr. Cynthia Willey, University of Rhode Island,
during 1995 to 1998.
Patients were recruited from three sites affiliated with the study investigators.
These sites are a part of seven clinical sites in Rhode Island, which have
collaborated since 1987 as part of the Brown University Aids Program and
provide primary care services to over 75% of the HIV infected patients from
Rhode Island and the surrounding Massachusetts area. The study sites are listed
below:
1. The Miriam Hospital Immunology Center, which has the largest number of
ambulatory visits of HIV seropositive individuals and serves the majority of
HIV positive women in Rhode Island.
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2. Stanley Street Treatment and Resources, which provides primary care for
the indigent and intravenous drug users in the greater Fall River,
Massachusetts area.
3. Veteran's Affairs Medical Center in Providence, RI, which currently
provides care to approximately 60 HN positive seropositive men.
B. Data Collection
A standardized questionnaire was administered to patients meeting the eligibility
criteria who visited one of the three sites. The patients were told that the
questionnaire was about how they think and feel about their HN related
medications, and about different strategies that people use to take their
medications. Research assistants explained the questionnaire to the patients in a
private location on each site, and were available to answer questions while the
respondents were filling out the questionnaire.
Some patients did not complete the questionnaire at the clinic and were allowed to
fill out the questionnaire at home and mail it to the clinic. They were told that
they would each receive a $20 gift certificate after they had turned the
questionnaire in. The data was collected during the year 1996-97.
The survey questionnaire administered to the patients included questions to gather
data on demographics, living arrangements, education, employment, income,
insurance coverage, social support, side effects, and psychological measurement
scales. The information about the medication and several adherence related
questions were asked for each antiretroviral and protease inhibitor medication the
patient was on. The respondents responded to a set of questions for every drug
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they were prescribed. Of the 145 respondents, a subset of 77 respondents
responded to questions on protease inhibitor medications m addition to
antiretroviral medications. Thus, each respondent answered questions about each
drug they were on separately. The medications the respondents provided
information

on

included

antiretroviral

medications

like

AZT

zidovudine), DDI (videx, didanosine), DDC (hivid, zalcitabine), D4T

(retrovir,
(zerit,

stavudine), 3TC (epivir, lamivudine) and protease inhibitor medications like
saqinavir (invirase), ritonavir (norvir) and indinavir (crixivan). Responses were
also

obtained

sulfamethoxazole,

for

anti-

infective

clarithromycin,

medications

dapsone,

like

flucanazole,

trimethoprim
rifabutin

or
and

itraconazole. It was a self-reported questionnaire. All the questionnaires were
checked for completeness before the incentives were awarded.
C. Measures and Variables assessed

The questionnaire included questions regarding the following:
•

Demographics: age, gender, ethnicity, years of education, family income,
health insurance coverage, number of people in the household, and
employment status.

•

Current health status and mood status.

•

Social support: emotional, financial, physical support from family and friends .

•

Physical functioning: severity of bodily pain, number of days in bed in the
past two weeks, number of hospitalizations in the past year, interference of
pain with normal work in the past four weeks, T-cell count last tested. The
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Medical Outcomes Study (MOS) 36 item quality of life scale was included
(54).
•

Medical status: self reported disease and medication history, number of doses
missed in the past one month, number of doses missed in the past three
months.

•

Coping: ways in which people cope with HIV and its treatment. The Ways of
coping scale as modified by Dunkel-Schetter, Feinstein, Taylor, Flake (53) to
suit their study on cancer patients was included.

D. Assessment of Medication Adherence

Medication adherence with anti-retroviral and protease inhibitor medications was
assessed separately using data on two scales. The adherence was calculated
separately for antiretroviral and protease inhibitor medications because the
respondents had answered questions for each type of medication separately. The
two scales used to measure adherence are:
1. Medication Adherence Scale: MAS or Medication Adherence Scale is a

previously validated scale to measure adherence (55). It contains six questions
that are answered yes or no. A positive response indicates inadequate
adherence.
•

During the last 3 months, have you ever stopped taking your antiretroviral
medication because you felt worse?

•

During the last 3 months, have you ever forgotten to take antiretroviral
medication?
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•

During the last 3 months, have you at times been careless about taking
antiretroviral medication?

•

During the last 3 months, have you ever taken less of your antiretroviral
medicine than your doctor prescribed because you felt better?

•

During the last 3 months, have you ever taken less of your antiretroviral
medicine than your doctor prescribed because you felt worse?

•

Since you began taking protease inhibitor/antiretroviral medication, have you
ever purposely taken more/less of the medicine than your physician prescribed
or discontinued your medication?

On the response options, a "Yes" was coded as "2" and "No" was coded as "l ".
The score for the scale was obtained by summing the response codes on each item
on the scale. The range for the scales could thus be 6 to 12. Any respondents who
had not responded to more than one item were dropped from the analyses. The
scores were calculated separately for antiretroviral drugs and protease inhibitor
drugs. The MAS score for each anti-retroviral drug was calculated. Further, the
average score for all the anti-retroviral drugs was calculated and used in the
analyses. Similarly, the scores for all protease inhibitor drugs were calculated and
averaged.
Percentage Adherence:
Percentage adherence in the past one month was calculated using the answers to
the questions "During the past month, about how many times did you miss a dose
of the medication?" and "How often do you take this medication?" The responses
to the question "How often do you take this medication" were used to determine
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the total doses prescribed for each medication. From this question, the number of
doses the respondent should take for one month was calculated.
Percentage adherence in the past one month was calculated using the formula:

Percentage adherence =

1-

Number of doses of
medication missed in the past one month
Total number of doses
in the past one month

x 100

The percentage adherence in the past one-month was determined separately for
antiretroviral drugs and protease inhibitors. Protease inhibitor medications were
newly introduced at the time of the study, and hence it was thought interesting to
explore adherence to these drugs separately. The percentage adherence was
calculated for all the antiretroviral drugs and was averaged to get an average
percentage adherence in the past one month to all antiretroviral medications the
patient was on. Similarly, the percentage adherence was determined for all
protease inhibitors and was averaged. Thus, the range of values for percentage
adherence can be from 0 to 100.
Two definitions were followed to classify respondents as adherent or nonadherent. A respondent was classified as "adherent" if his percentage adherence
was 100, i.e. he reported not missing any dose in the past one month. This
stringent cut off was chosen to offset the likely overestimation of adherence by
respondents. A big drawback of self-reported adherence is that the patients tend to
overestimate the adherence (23,24). All the respondents having less than 100 %
adherence were classified as "non-adherent". But since in the real world, it would
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be almost impossible to attain 100% adherence, an alternative cut off of 95% was
also chosen.
For the second cut-off, all patients showing 2:95% adherence were classified as
"adherent" and those showing <95% adherence were classified as "non-adherent".
This cut off was chosen based on a study by Paterson D et al. (14) that reported
that even with adherence as high as 95%, only 80% of patients had undetectable
viral loads. The coding system followed was: "1" for adherence, and "O" for nonadherence.
Coping: Coping was assessed using the responses to a 50-item scale. The scale

gives the frequency of use of each coping style by the respondents. The questions
were of the type: In the last month, how often did you think, feel or do each item?
The response options to the items are in form of a likert scale as follows:
1=Never; 2= Rarely; 3=0ccasionally; 4= Often; 5= Very often
This scale was taken from the Ways of Coping Questionnaire (WOC) developed
by Folkman and Lazarus (44). It describes a broad range of behavioral and
cognitive coping strategies that a person might use during a stressful encounter.
This scale was revised by Lazarus, Folkman, Dunkel-Schetter to develop a
questionnaire with 51 items. This scale was again modified by Dunkel-Schetter,
Feinstein, Taylor, Flake (53) to suit their study on cancer patients. These were the
first coping patterns to be identified with a large and heterogeneous sample of
cancer patients and they are similar to those identified with a large sample of
community residents experiencing a variety of life stressors. It appears that they
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may be representative of universal dimensions of coping. The five factors
developed as a result of factor loadings were:
Behavioral Escape- Avoidance: sum of nine items (item numbers 29, 23, 24, 35,
39, 18, 3, 5, 25).
Focus on positive: sum of eight items (item numbers 26, 27, 17, 41, 21, 28, 14,
47).
Distancing: sum of 12 items (item numbers 40, 30, 33, 9, 10, 11, 50, 37, 15, 32,
48, 52).
Cognitive-Escape-Avoidance: sum of nine items (item numbers 7, 44, 45, 42,
43, 46, 8, 51, 12).
Seek and Use Social Support: sum of eleven items (item numbers 4, 34, 22, 20,
16, 49, 13, 31, 6, 19, 1).
Description of these items is in appendix ill.
The final score for each factor was obtained by summing the responses on the
items constituting that factor. Lazarus and Folkman (44) described this method of
raw sconng.
For example, the score for Behavioral Escape-Avoidance= Sum (qvi29 + qvi23+
qvi24+ qvi35+ qvi39+ qvi18+ qvi5+ qvi3+ qvi25)
For each factor, observations with more than two missing values were dropped
from the analyses.
E. Variables Used:

The following variables were determined to be of interest and were included in
the analyses.
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Dependent Variables:
1. Percentage adherence: to antiretroviral drugs in the past one-month. (100%
as cut off)- abbreviated as 100% A.V.
2. Percentage adherence: to antiretroviral drugs in the past one-month. (95% as
cut off)- abbreviated as 95% A.V.
3. Percentage adherence: to protease inhibitor drugs in the past one-month.
(100% as cut off)-abbreviated as 100% P.I.
4. Percentage adherence: to protease inhibitor drugs in the past one-month.
(95% as cut off) -abbreviated as 95% P.I.
5. Medication Adherence Scale for antiretroviral drugs: Dichotomous
measure of adherence- abbreviated as MAS A.V.
6. Medication Adherence Scale for protease inhibitor drugs: Dichotomous
measure of adherence- abbreviated as MAS P.I.
Independent Variables:
The IV's of primary interest were the coping styles. These were used as
continuous variables for univariate and bivariate analysis, but had to be
categorized for use in final logistic regression analysis. The coping styles are:
Seeking social support - abbreviated as 'sss'.
Distancing -abbreviated as 'dis'
Focusing on positive- abbreviated as 'fop'
Behavioral escape avoidance -abbreviated as 'bea'
Cognitive escape avoidance -abbreviated as 'cea'
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Demographic Variables
Age: The variable age was categorized into three groups of< 35 years, 35-41
years and 2: 42 years. The first category was coded as 0, the 35-41 years age
category was coded as 1, while the > 42 years age group was coded as 2 for the
analysis.
Gender: For the purpose of analysis, males were coded as '1' and females as 'O'.
Race: The variable race was dichotomized into 'whites' and 'non-whites'. The
'whites' were coded as 'l ', whereas 'native Americans', 'Hispanics', 'African
American, 'Asian' and others' were collapsed into a single category 'non-whites'
and were coded '0'.
Annual income: The respondents were dichotomized as having income of less
than $15,000 (coded as' 1'),or more than$ 15,000 (coded as 'O').
Years of Education: Respondents having attained more than 12 years of
education were coded as 'O' where as those with less than 12 years of education
were coded as ' 1'.
Insurance: The respondents which reported having any form of insurance were
coded as 'O', where as those without any insurance were coded as '1 '.
Clinical variables
Bodily pain: Respondents who reported moderate to severe bodily pain were
grouped into one category and were coded as '1 ', where as those which reported
none to mild pain were coded as 'O'.
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Times since diagnosis with HIV: Patients who had been diagnosed with HIV

before less than 2 years were coded as '1 ', those diagnosed before 3-4 years were
coded as '2', whereas those who were diagnosed before 5 years were coded as '3'.
CD4 count: The patients with CD4 cell count between 50-200 were coded as 'O',

whereas those with count between 201-500 were coded as '1 '.
Injection drug use: Occasional and regular drug users were coded as '1 ', while

those who were not drug users were coded as 'O'.
There were 13 7 respondents who were prescribed antiretroviral medications.
There were 77 respondents who were prescribed protease inhibitor medications.
Data Analysis:

The above-mentioned variables constitute the independent and dependent
variables as described. The associations between the independent variables and
the dependent variables were examined using bivariate and multivariate statistics.
The data was analyzed using the Statistical Analysis System (SAS) version 8.00
on the computers of Department of Applied Pharmaceutical Sciences, University
of Rhode Island.
The data was screened for normality, linearity and homoscedasticity. The variable
"adherence using MAS" was markedly negatively skewed for both antiretroviral
medications and protease inhibitor medications. Several transformations including
square root, exponential, log, were tried to make the variable normal. The variable
was dichotomized due to a markedly skewed distribution. All respondents with a
score of 6 were categorized as being "adherent" and those with score of 7 and

23

above were categorized as being "non-adherent", that is, any respond who
responded 'yes' to even a single question were categorized as being non-adherent.
Further, bivariate analyses were run between the primary independent variables
and all other variables and also between the primary dependent variables and all
other variables to check for the potential confounding variables. Bivariate
statistics were used to determine the association between each dependent variable
and each independent variable, excluding the independent variables of primary
interest i.e. copmg styles. Similarly, association between each primary
independent variable and other independent variables was determined. The
associations between each dependent variable (100% A.V., 95% A.V., 100% P.I.,
95% P.I., MAS A.V., MAS P.I.) and the independent variables (age, gender, race,
income, years of education, insurance, bodily pain, time since diagnosis, CD4
count, injection drug use) excluding the primary independent variables, i.e. the
coping styles, were explored using chi-square tests. The associations between
each primary independent variable (sss, dis, fop, bea, cea) and other independent
variables (gender, race, income, years of education, insurance, bodily pain, CD4
count, injection drug use) were explored using multiple T-tests. ANOVA's were
run to explore the association between the coping styles (ss, dis, fop, bea, cea) and
the variables "time since diagnosis" and "age".
Further, each primary independent variable (coping styles) was categorized into
three categories so that preliminary logistic regression models could be run
between each coping style and each dependent variable to assess the parametric
form. The primary independent variables were transformed into categorical
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variables as they did not show a linear relationship with the dependent variables
and hence could not be used as continuous variables in the final logistic models.
Each coping style was categorized into three level variables based on the
frequency distribution. Each coping style was categorized as "seldom used",
"used often" and "used very often". Further, these categorical independent
variables were transformed into dummy variables as follows:
Seeking Social Support:

ssshigh- 'using seeking social support very often'
sssmed- 'using seeking social support often
reference category- 'using seeking social support seldom'
Distancing:

dishigh- 'using distancing very often'
dismed- 'using distancing often
reference category- 'using distancing seldom'
Focusing on Positive:

fophigh- 'using focusing on positive very often'
fopmed- 'using focusing on positive often
reference category- 'using focusing on positive seldom'
Behavioral Escape Avoidance:

beahigh- 'using behavioral escape avoidance very often'
beamed- 'using behavioral escape avoidance often
reference category- 'using behavioral escape avoidance seldom'
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Cognitive Escape Avoidance:

ceahigh- 'using cognitive escape avoidance very often'
ceamed- 'using cognitive escape avoidance often
reference category- 'using cognitive escape avoidance seldom'
The variable 'age' was dummy coded as follows:
highage- >=42 years.
medage- 35-41 years.
reference category- < 35 years.
The variable 'time since diagnosis' was dummy coded as follows:
longtime- >= 5 years.
medtime- 3 to 4 years.
reference category- <=2 years.
Finally, logistic regression analysis was run to assess the effect of each coping
style on each dependent variable. Logistic models were run separately for each
independent variable with each dependent variable. Logistic regression models to
assess the effect of each primary independent variable on each dependent variable
were tested following the strategy described by David Kleinbaum. The 'chunk'
tests were performed to detect any interactions. The Maximum Likelihood ratio
tests were used to check for the significance of the interaction terms in the model.
The likelihood ratio test is a chi-square test that makes use of maximum
likelihood values. The full model with the interaction terms included and the
reduced model (without interaction terms) were compared using the difference
between the log likelihood statistics for the two models. Checking the effect of
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adding each variable to the model separately assessed confounding. Confounding
assessment followed the interaction assessment. The confounding assessment was
guided by considerations of validity and precision as described by Klienbaum.
Starting with the 'gold model', i.e. the model with all Independent variables
included, variables were sequentially dropped to check the effect on the odds
ratios and 95% confidence intervals. Only the variables whose deletion did not
caused a change in the odds ratio and C.I. were dropped. Separate models were
run for each primary independent variable due to high correlation between them.
Each primary independent variable was conceptually very different and separate
models were run to assess the effect of each primary l.V. on each D.V.
The logistic regression models are listed below:
For Anti-retroviral drugs:

1) Percentage adherence 100% cut-off (D.V.)= ssshigh + sssmed
2) Percentage adherence 100% cut-off (D.V.)= dishigh + dismed
3) Percentage adherence 100% cut-off (D.V.)= fophigh + highmed
4) Percentage adherence 100% cut-off (D.V.)= beahigh +beamed
5) Percentage adherence 100% cut-off (D.V.)= ceahigh + ceamed
6) Percentage adherence 95% cut-off (D.V.)= ssshigh + sssmed
7) Percentage adherence 95% cut-off (D.V.)= dishigh + dismed
8) Percentage adherence 95% cut-off (D.V.)= fophigh + highmed
9) Percentage adherence 95% cut-off (D.V.)= beahigh +beamed
lO)Percentage adherence 95% cut-off (D.V.)= ceahigh + ceamed
11) MAS adherence (D. V)= ssshigh + sssmed
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12) MAS adherence (D.V)= dishigh + dismed
13) MAS adherence (D.V)= fophigh + highmed
14) MAS adherence (D.V)= beahigh +beamed
15) MAS adherence (D. V)= ceahigh + ceamed
For protease-inhibitor drugs:
16) Percentage adherence 100% cut-off (D.V.)= ssshigh + sssmed
17) Percentage adherence 100% cut-off (D.V.)= dishigh + dismed
18)Percentage adherence 100% cut-off(D.V.)= fophigh + highmed
19) Percentage adherence 100% cut-off (D.V.)= beahigh +beamed
20) Percentage adherence 100% cut-off (D.V.)= ceahigh + ceamed
21)Percentage adherence 95% cut-off(D.V.)= ssshigh + sssmed
22) Percentage adherence 95% cut-off (D.V.)= dishigh + dismed
23) Percentage adherence 95% cut-off (D.V.)= fophigh + highmed
24) Percentage adherence 95% cut-off (D.V.)= beahigh +beamed
25)Percentage adherence 95% cut-off(D.V.)= ceahigh + ceamed
26) MAS adherence (D.V)= ssshigh + sssmed
27) MAS adherence (D.V)= dishigh + dismed
28) MAS adherence (D.V)= fophigh + highmed
29) MAS adherence (D.V)= beahigh +beamed
30) MAS adherence (D.V)= ceahigh + ceamed
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RESULTS
Table 1. Demographics and Clinical Characteristics of Patient Population
prescribed Anti-retroviral Medication:

A total of 137 patients were on anti-retroviral medication. These patients were
between the ages of 24 to 57. The median age was 38. An equal proportion of
respondents (34.09%) were between the age groups of 35-41 years and greater
than 42 years, where as 31.82% were less than 35 years of age. The majority of
the patients were males, who constituted 72.06% of the sample, whereas females
constituted 27.94% of the sample.
A majority of the respondents (65.18%) had more than 12 years of education.
72.99% of the sample reported that their health status was excellent to good.
Whites constituted 63.50% of the sample, while the non-whites (Native
Americans, Hispanics, Asians, African Americans and others) constituted 36.50%
of the sample. About 29.20% of the patients said that they lived alone, while
70.80% said that they lived with others. 61.24% of the patients reported that their
annual income was less than $15,000, while 38.76% reported that their annual
income was above $15,000. Only 16.06% of the patients reported as having no
insurance, while 83.74% reported as having some insurance.59.85% of the
patients reported that they experienced none to mild bodily pain, while 40.15%
reported that they experienced moderate to very severe bodily pain. 64.18% of the
patients reported that they had been diagnosed with HN for a time period greater
than 5 years. 47.92% of the patients reported that their T-cell count was less than
200 and 53.08% of the patients reported that their T-cell count was greater than
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200. Only 3.65% of the patients reported that they occasionally used intravenous
drugs, while the majority of the patients, 40.88% reported that they had never at
all or never in the past 6 months used intravenous drugs.
Table 2. Demographics and clinical characteristics of patient population
prescribed Protease-inhibitor medication:

A total of 76 patients were on protease-inhibitor medication. These patients were
between the ages of 24 to 57. The median age was 38. Of these, 40% were above
42 years, 36% between 35-41 years and 24% below 35 years of age. The majority
of the patients were males, who constituted 75.00% of the sample, whereas
females constituted 25.00% of the sample. A majority of the respondents
(77.33%) had more than 12 years of education. 80.52% of the sample reported
that their health status was excellent. Whites constituted 75.32% of the sample,
while the non-whites (Native Americans, Hispanics, Asians, African Americans
and others) constituted 24.68% of the sample. About 28.57% of the patients said
that they lived alone, while 71.43% said that they lived with others. 57.33% of
the patients reported that their annual income was less than $15,000, while
42.67% reported that their annual income was above $15,000. Only 12.99% of the
patients reported as having some insurance, while 87.01 % reported as having no
insurance.58.44% of the patients reported that they experienced none to mild
bodily pain, while 41 .56% reported that they experienced moderate to very severe
bodily pain. 59.74% of the patients reported that they had been diagnosed with
HIV for a time period greater than 5 years. 51.33% of the patients reported that
their T-cell count was less than 200 and 48.65% of the patients reported that their
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T-cell count was greater than 200. Only 2.60% of the patients reported that they
occasionally used intravenous drugs, while the majority of the patients, 41.96%
reported that they had never at all or never in the past 6 months used intravenous
drugs.
Table 3. Adherence with Anti-retroviral (A.V.) and Protease Inhibitor (P.I.)
Medications (Dependent Variables):
For patients on A.V Medications: With a 95% cut off (patients whose adherence

was above 95% were categorized as adherent, while those below 95% were
categorized as non-adherent), 85.61 % (n

=

113) of the patients were found to be

adherent, whereas 14.39% (n = 19) were found to be non-adherent.
With a 100% cut off (patients whose adherence was 100% were categorized as
adherent, while those below 100% were categorized as non-adherent), 47.73% (n
=

63) of the patients were found to be adherent whereas 52.27% (n

=

69) were

found to be non-adherent.
Using the MAS, 45.26% (62) patients were found to be adherent, while 54.74%
(75) patients were found to be non-adherent.
For patients on P.I Medications: With a 95% cut off (patients whose adherence

was above 95% were categorized as adherent, while those below 95% were
categorized as non-adherent), 86.67% (n

=

65) of the patients were found to be

adherent whereas 13.33% (n = 10) were found to be non-adherent.
With a 100% cut off (patients whose adherence was 100% were categorized as
adherent, while those below 100% were categorized as non-adherent), 49.33% (n
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=

37) of the patients were found to be adherent whereas 51.95% (n

40) were

=

found to be non-adherent.
Using the MAS, 48.05% (37) patients were found to be adherent, while 51.95%
(40) patients were found to be non-adherent.
Table 4. Frequency of use of each coping style (primary I.V.) by patients
prescribed

Anti-retroviral

and

those

prescribed

Protease

Inhibitor

Medications:
For patients on A.V. Medications: Patients were categorized into three groups

based on the frequency of use of the coping styles i.e. using coping style seldom,
using it often and using it very often. The majority (43.31%) of the patients
reported using "Focusing on positive" very often. Seeking social support,
distancing, Behavioral escape avoidance, cognitive escape avoidance and was
used very often by 35.43%, 38.89%, 40.00%, and 38.40% patients respectively.
For patients on P.I. Medications: Majority (44.59%) of the patients reported

using "Focusing on positive" very often. Seeking social support, distancing,
Behavioral escape avoidance, cognitive escape avoidance and was used very often
by 44.00%, 43 .24%, 40.85%, and 44.59% patients respectively. Thus there is no
trend or preference for use of any particular coping style by patients.
Table 5: Adherence status by frequency of use of coping style in patients on
Antiretroviral medications: Table 5 summarizes the adherence status of patients

on antiretroviral medication by their frequency of use of coping styles. The results
are comparable for 100% adherence and adherence as measured by MAS.
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Table 6: Adherence status by frequency of use of coping style in patients on
Protease inhibitor medications: Table 5 summarizes the adherence status of
patients on protease inhibitor medication by their frequency of use of coping
styles.
Table 7. Multiple Chi-Square Tests with Adherence to Antiretroviral
Medications with 100% cut off (Categorical Dependent Variable) and other
Categorical Independent Variables:
None of the independent variables was significantly associated with adherence in
the chi square test.
Table 8. Multiple Chi-Square Tests with Adherence to Antiretroviral
Medications with 95% Cut-off (Categorical Dependent Variable) and other
Categorical Independent Variables:
None of the variables showed a significant association with medication
adherence. The variables "insurance" and "time since diagnosis" did not have
enough sample size per cell and hence the chi-square was not a valid test to check
for the differences in the proportions of respondents who were adherent and those
who were non-adherent.
Table 9. Multiple Chi-Square Tests run with Adherence to Antiretroviral
Medications using MAS (Categorical Dependent Variable) and other
Categorical Independent Variables:
None of the variables showed a significant difference in their proportions of
adherent and non-adherent patients, suggesting no association between these
variables and adherence.
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Table 10. Multiple Chi-Square Tests with Adherence to Protease inhibitor
Medications with 100% cut off (categorical Dependent Variable) and other
Categorical Independent Variables.
The variable "gender" (p= 0.02) was found to be significantly different between
the adherent and non-adherent patients. Greater proportion of males were
adherent.

Table 11. Multiple Chi-Square Tests with Adherence to Protease Inhibitor
Medications using MAS (categorical Dependent Variable) and other other
Categorical Independent Variables:
The variables "annual family income"(fisher's p value= 0.16), "T-cell count" (pvalue = 0.03) were found to be significantly different between the adherent and
non-adherent patients. Respondents with annual income more than $15,000 and
those with T-cell count of less than 200 were found to be more adherent than
those with income less than $15,000 and those with T-cell count greater than 200.

Table 12. Multiple T tests with "Seeking social support" (Continuous
primary I.V.) and other Independent Variables (Categorical) for people
prescribed anti-retroviral medication:
The mean score on the variable "Seeking Social Support" was significantly
different between the patients with insurance and patients with no insurance (pvalue=0.0003). The mean score was also significantly different between patients
living alone and patients living with someone (p-value=0.005). The patients who
were insured and those who lived alone had greater mean score on "Seeking
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Social Support" as compared to those who were uninsured and those who did not
live alone.
Table 13. Multiple T tests with "Distancing" (Continuous primary l.V.) and
other Independent Variables (Categorical) for people prescribed antiretroviral medication:
The mean score on the variable "Distancing" was significantly different between
the patients living alone and patients not living alone (p-value=0.03). The patients
living alone had a greater mean score on the variable "Distancing" as compared to
those who did not live alone.
Table 14. Multiple T tests with "Focusing on Positive" (Continuous primary
I.V.) and other Independent Variables (Categorical) for people prescribed
an ti-retroviral medication:
The mean score on the variable "Focusing on Positive" was significantly different
between the patients with excellent/good health and patients with fair/poor health
(p-value=0.03). The score was also significantly different between the patients
living alone and those not living alone (p-value=0.05). Also, the mean score was
significantly different between patients with income <15,000 and those with
income 2: 15,000 (p-value=0.02).
Table 15. Multiple T tests with "Behavioral Escape Avoidance" (Continuous
primary I.V.) and other Independent Variables (Categorical) for people
prescribed anti-retroviral medication:
The mean score on the variable "Behavioral Escape Avoidance" was significantly
different between the patients living alone and those not living alone (p-
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value=0.03). The score was also significantly different between the patients with
none/mild pain and patients with moderate/severe pain (p-value=0.01). The
patients living alone and those with moderate to severe pain reported more
behavioral escape avoidance as compared to patients not living alone and those
with none to mild pain.

Table 16. Multiple T tests with "Cognitive Escape Avoidance" (Continuous
primary l.V.) and other Independent Variables (Categorical) for people
prescribed anti-retroviral medication:
The mean score on the variable "Cognitive Escape Avoidance" was significantly
different between the white patients and the non-white patients (p-value=0.01).
Whites had a significantly greater score on cognitive escape avoidance scale as
compared to the non-whites.

Table 17. ANOVA between the categorical l.V "Time Since Diagnosis",
"age" and continuous primary Independent Variables for people prescribed
An ti-retroviral medication:
None of the continuous primary I.V's showed significant differences across the
groups of "time since diagnosis" or "age".

Table 18. Multiple T tests with "Seeking social support" (Continuous
primary l.V.) and other Independent Variables (Categorical) for people
prescribed Protease-inhibitor medication:
The mean score on the variable "Seeking Social Support" was significantly
different between the patients with insurance and those without insurance (pvalue=0.002). The scores were also different between patients with none/mild

36

body pain and those with moderate/severe pain (p-value=0.03). The patients with
some insurance and those with moderate to severe pain reported using more
seeking social support as compared with those with no insurance and those with
none to mild pain.

Table 19. Multiple T-tests with "Distancing" (Continuous primary l.V.) and
other Independent Variables (Categorical) for people prescribed Proteaseinhibitor medications:
No significant difference was found in the means of the variable "distancing".

Table 20. Multiple T-tests with "Focusing on Positive" (Continuous primary
1.V.) and other Independent Variables (Categorical) for people prescribed
Protease-inhibitor medications:
The mean score on the variable "focusing on positive" was significantly different
between the patients with insurance and those without insurance (p-value=0.04).
The patients with some insurance reported using focusing on positive as
compared to those with no insurance.

Table 21. Multiple T-tests with "Behavioral Escape Avoidance" (Continuous
primary I.V.) and other Independent Variables (Categorical) for people
prescribed Protease-inhibitor medications:
The mean score on the variable "behavioral escape avoidance" was significantly
different between the patients living alone and those not living alone (pvalue=0.008).
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Table 22. Multiple T-tests with "Cognitive Escape Avoidance" (Continuous
primary I.V.) and other Independent Variables (Categorical) for people
prescribed Protease-inhibitor medications:
No significant difference was found in the means of the variable "Cognitive
Escape Avoidance".

Table 23. ANOV A between the Categorical Independent Variable "Time
since diagnosis", "age" and Continuous primary Independent Variables for
People prescribed Protease-inhibitor Medications:
There was significant difference in the means of the variable "Cognitive Escape
Avoidance" between the groups of variable "time since diagnosis" (p-value=0.02)
for people prescribed A.V. medications.
The results for patients on P.I. medications were non significant.

Table 24 to Table 47 summarize the final logistic regression models run between
each of the independent variables (coping styles) with each of the dependent
variables (100% A.V. , 95 % A.V., MAS A.V., 100% P.I. , 95 % P.I., MAS P.I.)
controlling for the potential confounding variables. In the bivariate tests, some
demographic and clinical variables were found to be significantly associated with
either some independent variable or some dependent variable, but none was found
to be significantly associated with both the independent variable and dependent
variable, and hence did not qualify to be a confounder. Introducing the variables
in ascending order as well as descending order assessed the effect of each
independent variable on the dependent variables. In the final model, 'behavioral
escape avoidance' was significantly associated with medication adherence as
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assessed by medication adherence scale for patients on antiretroviral medications.
The people who used behavioral escape avoidance very often are 60% less likely
to be adherent as compared to those who use this coping style seldom. Similarly,
people who used behavioral escape avoidance often are 70% less likely to be
adherent as compared to those who use this coping style seldom. BEA was also
significantly associated with adherence to antiretroviral medications using a 100%
cut off definition. The respondents using BEA very often are 70% less likely and
those using BEA often are 90% less likely to be adherent as compared to their
counterparts who use BEA seldom. All other logistic regression models were nonsignificant. Also, the final models revealed some interesting associations.
Education and living arrangement were also found to be significantly associated
with adherent to protease inhibitors as defined by 95% cut off. The respondents
with less than 12 years of education and those living alone were 90% less likely to
be adherent as compared with those with more than 12 years of education and not
living alone.
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Discussion

The purpose of this research was to assess coping with HIV as a predictor of
medication adherence. Two measures of medication adherence, MAS and
percentage adherence were used to assess the adherence to anti-retroviral and
protease-inhibitor medications. There is much uncertainly as to what definition or
method is best for measuring and assessing medication adherence. Hence,
classifying the respondents as being adherent or non-adherent was accomplished
using two scales to increase the validity. Both the scales gave data which was
self-reported by the patients. Two cut-offs were used for the percentage
adherence, 95% cut-off and 100% cut off. The 95% cut-off was chosen based on
literature review. The 100% adherence cut off, though seemingly unpractical, was
chosen because it has been well established how medication adherence dictates
the success of the medication therapy in HIV. It is absolutely imperative to adhere
strictly to the medication regimen. Given the repercussions of non-adherence and
missing even a few doses, strict adherence with the medication regimen is
imperative. Efforts should be directed to have the most stringent benchmark for
adherence, to identify the factors influencing and predicting adherence, and to use
this knowledge to develop dedicated interventions to eradicate the problem of
non-adherence. Disease states affect not only physical health, but also have
psychological implications. This is especially true in diseases like HIV, which has
no cure as yet, and leads to a slow death. The complexities of this disease are
enormous as it raises concerns regarding health, well-being, and social stigma,
confounded by a slow and sure death. Hence it is necessary to study the
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psychological factors that may influence various factors and behaviors, including
medication adherence. Coping is one such psychological domain that has not been
studied in relation to medication adherence in depth. Research with psychological
variables is complicated by the fact that there are no standard tools for
measurement of the domains. For this study, responses on the Ways of Coping
Questionnaire as modified by Dunkel-Schetter were used. In this study, most
patients coped in multiple ways with HIV. Patients did not report any single
pattern of coping more frequently than the other. This is consistent with the
results of the study by Dunkel-Schetter et al. in which they determined the coping
strategies used by cancer patients (53). The patients appear to use a large
repertoire of behaviors to cope flexibly with HIV, rather then rigidly adhering to a
particular coping style. This indicates to instability in the pattern of use of coping
styles. Lazarus and Folkman opine that coping strategies used keep changing
based on changing appraisal of stress level and situation. This situational aspect
and changing instable nature of coping makes assessment of coping styles a
difficult issue. Some authors have suggested measuring coping responses over
time and exploring sustainable trends over time.
For the patients prescribed protease inhibitors, males exhibited significantly
more adherence than females, using the percentage cutoff definition of adherence.
Gender has been inconsistently associated with medication adherence with HIV in
previous research. HIV+ women have also been shown to be more depressed than
males (56). This could have a bearing on adherence. In a retrospective cohort
study of antiretroviral medication adherence using New York State Medicaid
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data, women were less likely to be adherent and more likely to be depressed than
males (56). In a study to characterize the prevalence and predictors of diagnosed
depression among HIV patients on Medicaid, women were more likely to be
diagnosed with depression (57). The respondents who reported living alone
displayed significantly low adherence as compared to those not living alone. This
could be attributed to the important role social support plays in adherence
behavior. Previous research has demonstrated consistently that patient with good
social support display better adherence to medical therapy. This may be due the
support, care and reminders from the people living with the patients. Similarly,
those with education greater than 12 years are significantly more adherent as
compared with those with less than 12 years of education. Education imparts a
maturity and sense of responsibility. People with more education may be more
capable of understanding the disease and the importance of adherence better. Also
educated people may have more income as compared with those who are not
educated. Similarly, when adherence was assessed using MAS, patients with
greater family income were found to be significantly more adherent as compared
to those with low income. This could be because these patients are able to better
afford the medications. In the literature review, demographic variables have been
reported to be inconsistently associated with medication adherence. This
variability is rooted in the varied samples, varied definitions of adherence and
different measurement techniques. Some significant associations were observed

.

with the styles of coping used. Patients with some insurance and those with
moderate to sever pain reported using ' seeking social support' with significantly
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greater frequency as compared with those having no insurance and with mild

(
pain. This could be because patients with insurance could have more meaningful
social interactions and those in pain and suffering have a tendency to seek
external support. Patients with some insurance were also found to use 'focusing
on positive' to a significantly greater extent than those with no insurance.
In the final logistic regression models, the variable gender was significantly

associated with percentage adherence using the 100% cut off (OR, 0.2; 95% Cls,
0.08-0.8). Males were 80% less likely to be adherent to protease inhibitors as
compared with females. In the previous researches, gender has been inconsistently
associated with medication adherence.

For patients prescribed antiretroviral medications, those with some insurance
coverage and those living alone used 'seeking social support' with significantly
greater frequency as compared with those with no insurance and not living alone.
Also, patients living alone reported significantly more use of 'distancing' and
'behavioral escape avoidance' as compared with patients not living alone. This
could be because people who use passive coping strategies tend to be more
depressed and withdrawn. Patients having some insurance, those with good
health, living alone and having income greater than $15,000 reported using
'focusing on positive' significantly more than those without these attributes. With
the knowledge of these associations, people with the attributes associated with
non-adherent can be identified and targeted for interventions.

Coping- the results of this study indicate the coping style 'behavioral escape
avoidance', was significantly associated with adherence to antiretroviral
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medications as assessed by the medication adherence scale and 100% cut-ff.
Consistent with the results of previous research which assess effect of coping
strategies on various outcomes, behavioral escape avoidance seems to have an
inverse effect with medication adherence as assessed by medication adherence
scale in patients prescribed antiretroviral medications. Behavioral escape
avoidance is known to involve behavioral signs of avoidance such as social
withdrawal, impulsivity and drug use. The patients who use this coping style very
often and often are 80% and 90% less likely to be adherent as compared to those
who seldom use behavioral escape avoidance. Use of behavioral escape avoidance
was found to be significantly associated with percentage adherence to
antiretroviral drugs using the 100% cut off. The patients who use this coping style
'very often' and 'often' are 70% and 90% less likely to be adherent as compared
to those who seldom use behavioral escape avoidance This result is in agreement
with that obtained by Singh et al. (49) in a study of predictors in a sample of 123
HIV+ patients. Singh et al. used the Billings and Moos coping inventory to assess
the active-cognitive, active-behavioral or avoidance coping used by the
respondents. The results showed that 'avoidance' coping was significantly
correlated with non-adherence. Avoidance coping involved strategies like denying
that the problems exists, or indirectly reducing tension by behaviors like eating
and smoking. These strategies are very similar to those that constitute behavioral
escape avoidance in this study. Adherence was measured by refill adherence and
patients who obtained <90% or refills in the preceding six months were
considered non-adherent. In a prospective study involving 46 patients, Singh et al.

44

(

(19), utilized the 'Ways of coping questionnaire' to assess coping styles and their
association with medication refill adherence at 6 months. The authors reported
that adherence was significantly associated with better adaptive coping and non
adherence with poor coping. Although in this research no association was found
between adaptive coping styles like seeking social support or focusing on
positive, non-adherence was significantly associated with behavioral escape
avoidance. Although the previous researchers have used different coping scales
for assessing coping as predictor of medication adherence, the coping behaviors
involving escape avoidance strategies have consistently been associated with nonadherence.
This indicates that patients who exhibit behavioral escape avoidance tend to be
less adherent and is a group, which should be focused for behavioral intervention.
The conceptualization of adherence as the extent to which the patient follows
medical instructions is an oversimplification of a multidimensional complex
construct. It is now agreed upon that adherence is the extent to which a patient's
behavior- taking medications, following a diet, and/or executing lifestyle changes,
corresponds with agreed recommendations from health care provider (58).
Adherence involves a motivated behavioral change. This broader view of
adherence highlights the importance of psychological constructs and predictors of
adherence. This study is an addendum to and compelling support to the previous
researches that have investigated psychological predictors to adherence. The
results obtained are within some limitations, which despite diligence in statistical
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methodology, could have contributed significantly to the results. These limitations
are discussed in the following paragraph.
Limitations: The limitations, in part were due to the nature of the data and also

the lack of reliable and foolproof measures for the variables such as medication
adherence.
The sample size was only 145. Many variable distributions were skewed.
Statistical techniques were used to rectify this shortcoming, but the skewness may
indicate selection bias.
Self-reported data: A major shortcoming was the fact that the data was self-

reported. The validity of self-reports is questionable as it lends itself to patient's
recollection of the past. Recall bias plagues self-reports. There is a degree of
subjectivity that seeps in as the responses depend on the situational mood of the
respondent, education, social desirability concerns. These might influence the
patient's ability and willingness to give accurate responses.
Measurement: The lack of any standard for the measurement and quantification

of medication adherence is another limitation. The varied assessment techniques
and definitions used for adherence and the varied results in adherence studies
stand evidence to this.
This study was an effort to work within these limitations and tries to assess coping
as a predictor of medication adherence. More research with more objective
measures needs to be carried out on a larger sample to make the results
generalizable to the population.

46

CONCLUSION

The study to assess coping as a predictor of adherence with HIV medication has
produced some interesting results. For both anti-retroviral and protease-inhibitor
medications, approximately 85% patients were adherent based on the 95% cut-off.
This degree of adherence, though high is still inadequate in HIV. In contrast, the
100% cut-off and MAS showed disappointing results . 50-55% of the patients
were non-adherent on these scales. A majority of patients (43.31 %) on
antiretroviral medications use "focusing on positive" very often. Majorities of the
patients tend to use all coping styles very often.
Contrary to expectations, the final logistic models were not significant, suggesting
no association between coping styles and medication adherence. Only 'behavioral
escape avoidance' was found to be significantly associated with adherence to
antiretroviral medications when assessed using MAS and 100% cut off. This is
consistent with previous research findings. Patients using avoidance strategies can
be identified and targeted for behavioral interventions to improve adherence
behavior. This association, however was not found with adherence using other
measures like percentage cut offs. These results however, are from statistical
manipulations of data on merely 145 patients. Moreover, the adherence was selfreported. Measuring adherence is an extremely complex issue and self-reports are
plagued by errors of overestimation and recall bias. The results obtained were
within the limitations of limited sample size and self-reported adherence. Given
the critical importance of adherence, focused efforts of identifying predictors of
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adherence usmg reliable and objective measures of adherence are essential.
Psychological factors are important determinants of health, well-being and quality
of life of patients. For a disease such as HIV, factors influencing medication
adherence needs to be identified and evaluated to develop interventions that can
solve the problem of non-adherence and help make maximum good of the
therapies available. More research needs to be done on such factors, including
cop mg.
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Appendix I- Result Tables
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Table 1: Demographics and Clinical Characteristics of Patient Population
prescribed Anti-retroviral Medication:
Demographic
Variables
Age
< 35 yrs.
35-41 yrs.
'.:'.: 42 _}'!"_S.
Yrs. of education
<12 yrs.
'.:'.: 12 yrs.
Gender
Female
Male
Race
Whites
Non-whites:
-Native American
-Hispanic
-Asian
-African American
-Others
Living arrangement
Alone
With others
Annual Household
Income
<1 5,000
> 15,000
Insurance
Some
None

N(%)

42(31.82)
45(34.09)
45(34.09)
46(34.85)
86(65.18)

38(27.94)
98(72.06)
87(63 .50)
50(36.50)

40(29.20)
97(70.80)
79(61.24)
50(38.76)

22(16.06)
115(83.74)
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Mean=39.24
Median=38
Min=24 MaX:=57
S.D.= 7.55
Mean=12.00
Median=12
Min=O Max=22
S.D.=3.04

(

Clinical Variables
Bodily pain
None-Mild
Moderate-V.Severe
Current Health Status
Excellent-Good
Fair-Poor
Time Since Diagnosis
< lmonth-2years
3-4 years
=::: 5 years
T-cell Count
::::200
>200
IV Drug Use
Never or not in past 6
months
Occasionally

N(%)

82(59.85)
55(40.15)
100(72.99)
37(27.01)
23(17.16)
25(18.66)
86(64.18)
61(46.92)
69(53.08)
56(40.88)
5(3.65)
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Table 2: Demographics and Clinical Characteristics of Patient Population
prescribed Protease-inhibitor Medication:
Demographic
Variables
Age
< 35 yrs.
35-41 yrs.
2: 42 yrs.
Yrs. of education
<12 yrs.
2: 12 yrs.
Gender
Female
Male
Race
Whites
Non-whites:
-Native American
-Hispanic
-Asian
-African American
-Others
Living arrangement
Alone
With others
Annual Household
Income
<15,000
> 15,000
Insurance
Some
None

N(%)

18(24.00)
27(36.00)
30(40.00)
17(22.67)
58(77.33)

19(25.00)
57(75.00)
58(75.32)
19 (24.68)

22(28.57)
55_.(71.43)
43(57.33)
32(42.67)

10(12.99)
67(87.01)
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Mean=39.37
Median=38
Min=24 Max=57
S.D.= 7.44
Mean=12.88
Median=12
Min=O Max=22
S.D.=3.19

Clinical Variables
Bodily pain
None-Mild
Moderate-V.Severe
Current Health Status
Excellent-Good
Fair-Poor
Time Since Diagnosis
<lmonth-2years
3-4 years
::: 5 years
T-cell Count
::::200
>200
IV Drug Use
Never or not in past 6
months
Occasional!Y_

N(%)

45(58.44)
32(41.56)
62(80.52)
15(19.48)
15(19.58)
16(20.78)
4659.74)
36(48.65)
38(51.35)
32(41.56)
2(2.601
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Table 3: Adherence with Anti-retroviral (A.V.) and Protease Inhibitor
Medications (Dependent Variables):
Dependent Variable
Antiretroviral Medication
AV. 95% cut-off
AV. 100% cut-off
MAS Adherence
Protease Inhibitor Medication
P .I. 95% cut-off
P.I. 100% cut-off
MAS Adherence

Adherent
Number_{%l

Non-adherent
Number_{%}

113 (85.61)
63 (47.73)
62(45.26)

19 (14.39)
69 (52.27)
75(54.74)

65 (86.67)
37 (49.33)
37(48.05)

10 (13 .33)
38 (50.67)
40(51 .95)
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Table 4: Frequency of use of each coping style (primary I.V.) by patients
prescribed Anti-retroviral and those prescribed Protease Inhibitor
Medications:
Coping style

Seldom
N(%)

Often
N(%)

Patients Prescribed Antiretroviral Medications:
Seeking Social
36 (29.27)
44 (35.77)
SU_.2.2_0rt
Distancing
39 (31.97)
35 (28.69)
Behavioral Escape
32 (26.45)
41 (33.88)
Avoidance
32 (26.45)
Cognitive Escape
41 (33.88)
Avoidance
Focusin__g_ on Positive
37 (29.84)
35 (28.23)
Patients Prescribed Protease-inhibitor Medications:
Seeking Social
23 (30.67)
20 (26.67)
Su_QQ_ort
22 (29.33)
20 (44.00)
Distancin__g_
Behavioral Escape
23 (31.08)
25 (33.78)
Avoidance
18 (25.35)
24 (33.80)
Cognitive Escape
Avoidance
16 (21.62)
25 (33.78)
Focusin__g_ on Positive
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Very
often
N_{_%l
43 (34.96)
48 (39.34)
48 (39.67)
48 (39.67)
52 (41.94)
32 (42.67)
31 (26.67)
26 (35.14)
29 (40.85)
33 (44.59)

Table 5: Adherence status by frequency of use of coping style in patients on
Antiretroviral medications:
Adheren
ce
CoQini:;

SSS very
often
SSS

100% adherence
Non-adh.
Adh.
N(%)
N(%)
21 (48.8)
22 (51.2)

95% adherence
Adh.
Non-adh.
N(%)
N(%)
37 (86.1)
6 (13.9)

22 (50.0)

22 (50.0)

38 (86.3)

6 (13.7)

16 (44.4)

20 (55.6)

32 (88.8)

4(11.1)

26 (54.1)

22 (45.8)

43 (89.5)

5 (10.5)

16 (45.7)

19 (54.3)

29 (82.8)

6 (17.2)

18(46.2)

21 (53.8)

35 (89.7)

4 (10.3)

25 (48.0)

27 (51.9)

49 (94.2)

3 (5.7)

18(51.4)

17 (48.5)

28 (80.0)

7 (20)

16 (45.7)

16 (43.2)

21 (56.7)

31 (83.7)

6 (16.3)

15 (40.5)

23 (47.9)

25 (52.1)

40 (83.3)

8 (16.6)

20 (40.0)

15 (36.5)

26 (63.4)

35 (85.3)

6 (14.7)

15 (34.8)

28(65.1)

21 (65.6)

11 (34.4)

31 (96.8)

1 (3.2)

21(65.6)

25 (52.0)

23 (47.9)

42 (87.5)

6 (12.5)

23 (47.9)

11(34.3
8)
25
(52.1)

17 (41.4)

24 (58.6)

33 (80.4)

8 (19.5)

17 (38.6)

27(61.4)

16 (50.0)

16 (50.0)

30 (93.7)

2 (6.3)

17 (51.5)

16
(48.8)

often
SSS

seldom
dis very
often
dis
often
dis
seldom
fop
very
often
fop
often
fop
seldom
bea
very
often
bea
often
bea
seldom
cea
very
often
cea
often
cea
seldom
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MAS adherence
Adh.
Non-adh.
N(%)
N(%)
20(44.4) 25(55.5
6)
23(50.0) 23(50.0
0)
14(38.8) 22(61.1
1)
24(48.9) 25(51.0
2)
16(42.l) 22(57.8
9)
18(46.l) 21(53.8
5)
26(47.2) 29
(52.7)
19
(54.2)
22
(59.4)
30
(60.0)

Table 6: Adherence status by frequency of use of coping style in patients on
Protease inhibitor medications:

SSS

100% adherence
Adh.
Non-adh.
N(%)
N(%)
16 (50.0)
16 (50.0)

SSS

13 (56.5)
7 (38.8)

10 (43.51
11 (61.9)

MAS adherence
Adh.
Non-adh.
N(%)
N(%)
16 (50.00)
16 (50.00)
12 (60.00)
8 (40.001
12 (52.17)
11 (47.83)

14 (45.1)

17 (54.9)

17 (51.52)

16 (48.48)

12 (57.1)
10 (47.6)

9 (42.9)
11 (52.4)

7 (35.00)
12 (54.55)

13 (65.00)
10 (45.45)

15 (48.3)

16 (61.7)

17 (51.52)

16 (48.48)

11 (44.0)
10 (58.8)

14 (56.0l
7 (41.1)

11 (44.00)

8 (50.00)

14 (56.00)
8 (50.00)

16 (51.6)

15 (48.3)

12 (46.15)

14 (53.85)

9 (37.5)
11 (61.1)

15 (62.5)
7 (38.9)

10 (40.00)
13 (56.52)

15 (60.00)
10 (43.48)

15 (57.6)

11 (42.3)

15 (51.72)

14 (48.28)

11 (44.0)
10 (55.5)

14 (56.0)
8 (44.4)

12 (50.00)
9 (50.00)

12 (50.00)
9 (50.00)

Adherence
Co[!in1:;

very
often
sss often
seldom
dis very
often
dis often
dis
seldom
fop very
often
fo..2._ often
fop
seldom
bea very
often
bea often
bea
seldom
cea very
often
cea often
cea
seldom
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Table 7: Multiple Chi-Square Tests with Adherence to Antiretroviral
Medications with 100% cut off (Categorical Dependent Variable) and other
Categorical Independent Variables.
Categorical I.V.

Adherent

Non-Adherent
O/o

N_(o/tl_

Age
< 35 yrs.
42.55 (20)
57.45 (27)
35-41 yrs.
51.11 (23)
48.89 (22)
50.00 (20)
50.00 (20)
2: 42 J'!'_S.
Yrs. of education
<12 yrs.
53.49 (23)
46.51 (20)
51.14 (45)
48.86_(43)
: : : 12 yrs.
Gender
Male
46.32 (44)
53.68 (51)
Female
52.78 (19)
42.22 (17)
Insurance
None
38.10 (8)
61.90 (13)
Some
49.07 (53)
50.93 (55)
Current Health
Status
48.45 (47)
51.55 (50)
Good-Excellent
Poor-Fair
45.71 (16)
54.29 _(19)
Ethnicity
50.00 (42)
50.00 (42)
Whites
Non-Whites
44.68 (21)
55.32 (26)
Living
Arrangement
55.26 (21)
Alone
44.74 (17)
48.94 (46)
51.06 (48)
With Others
Annual Family
Income
<15,000
50.00 (38)
50.00 (38)
53.06 (26)
>15,000
46.94_(23)
Bodily Pain
51.85 (28)
None-Mild
48.15 (26)
47.44 (37)
52.56 (41)
Moderate-Sever
Time Since
Diagnosis
<1 month-2 years
46.43 (39)
53.57 (45)
54.17 (13)
45.83 (11)
3-4 years
50.00 (11)
> 5 years
50.00 (11)
T-Cell Count
54.55 (36)
45.45 (30)
:s 200
53.33 (32)
46.67 (28)
>200
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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p-value

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

Table 8: Multiple Chi-Square Tests with Adherence to Antiretroviral
Medications with 95% Cut off (Categorical Dependent Variable) and other
Categorical Independent Variables.
Categorical I.V.
Age
< 35 yrs.
35-41 yrs.
~42~s.

Adherent
O/o

Non-Adherent

91.94 (43)
86.67 (39)
77.50 (31)

8.51 (4)
13.33 (6)
22.50 (9)

p-value

%

Yrs. of education
<12 yrs.
79.07 (34)
20.93 (9)
88.64 (78)
11.36 (10)
> 12~s.
Gender
Male
86.32 (82)
13.68 (13)
Female
83.33 (30)
16.67 (6)
Insurance
None
95 .24 (20)
4.76 (1)
Some
84.26 (91)
15.74 (17)
Current Health
Status
82.47 (80)
5.71 (2)
Good-Excellent
17.53 (17)
Poor-Fair
94.29 (33)
Ethnicity
16.67 (14)
Whites
83.33 (70)
10.64 (5)
Non-Whites
89.36 (42)
Living
Arrangement
Alone
78.95 (30)
21.05 (8)
11.70 (11)
With Others
88.30 (83)
Annual Family
Income
13.16 (10)
<15,000
86.84 (66)
16.33 (8)
>15,000
83.67 (41)
Bodily Pain
16.67 (13)
None-Mild
83.33 (65)
Moderate-Sever
88.89 (48)
11.111_6)
Time Since
Diagnosis
<1 month-2 years
92.86 (78)
7.14 (6)
3-4 years
66.67 (16)
33.33 (8)
77.27 (17)
22.73 (5)
> 5_years
T-Cell Count
83.33 (55)
16.67 (11)
::::200
>200
86.67 (52)
13.33 (8)
Note: If a :s._0.05 then p- value is significant, NS= Non Significant
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NS

NS

NS

-

NS

NS

NS

NS

NS

-

NS

Table 9: Multiple Chi-Square Tests with Adherence to Antiretroviral
Medications using MAS (Categorical Dependent Variable) and other
C a te_g_onca
. I I n d e_E._en d en t V ana
' bl es.
Categorical I.V.
Adherent
Non-Adherent
p-value
%
%
Age
< 35 yrs.
37.50 (18)
62.50 (30)
NS
35-41 yrs.
51.06 (24)
48.94 (23)
47.62 (20)
53.38 (22)
~42~.
Yrs. of education
<12 yrs.
47.83 (22)
52.17 (24)
NS
44.44 (40)
55.56 (50)
> 12 _TI_S.
Gender
Male
43.88 (43)
56.12 (55)
NS
Female
47.37 (18)
52.63(20)
Insurance
None
45.45 (10)
NS
54.55 (12)
Some
44.46 (50)
55.36 (62)
Current Health
Status
Good-Excellent
46.00 (46)
54.00 (54)
NS
Poor-Fair
43.24 (16)
56.76 (21)
Ethnicity
Whites
48.28 (42)
51.72 (45)
NS
Non-Whites
40.82 (20)
59.18 (29)
Living
Arrangement
Alone
40.00 (16)
60.00 (24)
NS
With Others
47.42 (46)
52.58 (51)
Annual Family
Income
<15,000
55.70 (44)
44.30 (35)
NS
>15,000
46.00 (23)
54.00 (27)
Bodily Pain
54.88 (45)
None-Mild
45 .12 (37)
NS
Moderate-Sever
45.45 (25)
54.55 (30)
Time Since
Diagnosis
<l month-2 years
44.19 (38)
55.81 (48)
NS
3-4 years
44.00 (11)
56.00 (14)
> 5_x_ears
47.83 (11)
52.17(12)
T-Cell Count
NS
_'.S200
39.13 (27)
60.87 (42)
>200
50.82 (31)
49.18 (30)
Note: If a s_0.05 then p- value is significant, NS= Non Significant
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Table 10: Multiple Chi-Square Tests with Adherence to Protease inhibitor
Medications with 100% cut off (categorical Dependent Variable) and other
C a t e_g_onca
. 1 I n d e_p_en d ent V ana
. bl es.
Categorical I.V.
Adherent
Non-Adherent
p-value
O/o
O/o
Age
< 35 yrs.
53.33 (16)
46.67 (14)
NS
35-41 yrs.
48.15 (13)
51.85 (14)
44.44 (8)
55.56 (10)
~ 42 J-'!'_S.
Yrs. of education
<12 yrs.
50.00 (8)
50.00 (8)
NS
50.00 (29)
50.00 (29)
> 12J-'!'_S.
Gender
Male
57.14 (32)
42.86 (24)
0.02*
Female
26.32 (5)
73 .68 (14)
Insurance
None
33.33 (3)
66.67 (6)
NS
Some
51.52 (34)
48.48 (32)
Current Health
Status
Good-Excellent
50.00 (30)
50.00 (30)
NS
53 .33 (8)
Poor-Fair
46.67 (7)
Ethnicity
Whites
50.88 (29)
49.12 (28)
NS
Non-Whites
41.18 (7)
58.82 (10)
Living
Arrangement
NS
Alone
50.00 (10)
50.00 (10)
50.91 (28)
49.09 (27)
With Others
Annual Family
Income
<15,000
45.24 (19)
54.76 (23)
NS
>15,000
53.13(17)
46.88 (15)
Bodily Pain
None-Mild
52.38 (22)
47.62 (20)
NS
Moderate-Sever
45.45 (15)
54.55 (18)
Time Since
Diagnosis
<l month-2 years
47.92 (23)
52.08 (25)
NS
3-4 years
50.00 (7)
50.00 (7)
53.85 (7)
46.15(6)
~ 5_y_ears
T-Cell Count
40.63 (13)
NS
59.38 (19)
:::: 200
>200
52.50 (21)
47.50 (19)
Note: If a :s_0.05 then p- value is significant, NS= Non Significant

65

Table 11: Multiple Chi-Square Tests with Adherence to Protease Inhibitor
Medications using MAS (categorical Dependent Variable) and other
C at e_g_onca
. 1 I n d e_..E_en d ent V ana
. bl es.
Categorical I.V.
Adherent
Non-Adherent
p-value
O/o
%
Age
< 35 yrs.
50.00 (14)
50.00 (14)
NS
35-41 yrs.
44.44 (12)
55.56 (15)
50.00 (11)
50.00 (11)
2: 4 2 J'.!:_S .
Yrs. of education
<12 yrs.
43.71 (7)
56.25 (9)
NS
2: 12 yrs.
50.00 (30)
50.00 (30)
Gender
Male
50.88 (29)
49.12 (28)
NS
Female
36.84 (7)
63 .16 (12)
Insurance
None
50.00 (5)
50.00 (5)
Some
47.76 (32)
52.24 (35)
Current Health
Status
Good-Excellent
50.00 (31)
50.00 (31)
NS
Poor-Fair
40.00 (6)
60.00 (9)
Ethnicity
Whites
51.72 (30)
48.28 (28)
NS
Non-Whites
38.89 (7)
61.11 (11)
Living
NS
Arrangement
Alone
45.45 (10)
54.55 (12)
With Others
49.09 (27)
50.91 (28)
Annual Famil:y
Income
0.90
<15,000
39.53 (17)
60.47 (26)
fisher=O .16
56.25 (18)
43.75 (14)
*
2:15,000
Bodil:y Pain
None-Mild
51.11 (23)
48.89 (22)
NS
Moderate-Sever
43.75 (14)
56.25 (18)
Time Since
Diagnosis
<1 month-2 years
45.65 (21)
54.35 (25)
NS
3-4 years
50.00 (8)
50.00 (8)
53.33 (8)
46.67 (7)
2: 5_years
T-Cell Count
0.03*
33.33 (12)
66.67 (24)
200
>200
57.89 (22)
42.11 (16)
Note: If a :s_0.05 then p- value is significant, NS= Non Significant

:s
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Table. 12: Multiple T tests with "Seeking social support" (Continuous
primary I.V.) and other Independent Variables (Categorical) for people
prescribed anti-retroviral medication:
Inde_p_endent Variables
Means
_p_-value
Yrs. of education
<12 yrs.
34.61
NS
33.09
:::: 12_ES.
Gender
Male
33 .6
NS
Female
33 .7
Insurance
0.0003*
27.5
None
34.7
Some
Current Health Status
Good-Excellent
34.0
NS
Poor-Fair
32.2
Ethnicity
33.6
NS
Whites
Non-Whites
33.5
Living Arrangement
0.005*
Alone
36.9
32.2
With Others
Annual Family Income
NS
<15,000
32.9
>15,000
34.2
Bodily Pain
NS
None-Mild
32.5
Moderate-Sever
35 .3
Years of Education
NS
<12 years
34.4
>12 years
33.2
T-Cell Count
32.7
NS
:s 200
34.4
>200
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table. 13: Multiple T tests with "Distancing" (Continuous primary I.V.) and
other Independent Variables (Categorical) for people prescribed antiretroviral medication:
Indep_endent Variables
Yrs. of education
<12 yrs.
2: 12 yrs.
Gender
Male
Female
Insurance
None
Some
Current Health Status
Good-Excellent
Poor-Fair
Ethnicity
Whites
Non-Whites
Living Arrangement
Alone
With Others
Annual Family Income
<15,000
>15,000
Bodily Pain
None-Mild
Moderate-Sever
Years of Education
<12 years
>12 _years
T-Cell Count

Means

_1!_-value

34.71
35.84

NS

36.7
33.2

NS

36.5
34.9

NS

36.1
33.6

NS

33.8
36.7

NS

38.7
33.9

0.03*

35.2
36.6

NS

34.1
36.4

NS

35.3
35.1

NS

~200

34.0
>200
36.1
Note: If a ~0.05 then p- value is significant, NS= Non Significant
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Table. 14: Multiple T tests with "Focusing on Positive" (continuous primary
I.V.) and other Independent Variables (Categorical) for people prescribed
an ti-retroviral medication:
lnde_Qendent Variables
Means
_p_-value
Yrs. of education
<12 yrs.
26.61
NS
> 12 yrs.
25.09
Gender
Male
25.9
NS
Female
24.6
Insurance
None
21.8
0.007*
Some
26.2
Current Health Status
Good-Excellent
0.03*
26.3
Poor-Fair
23.5
Ethnicity
Whites
25.0
NS
Non-Whites
26.7
Living Arrangement
Alone
27.4
0.05*
With Others
24.8
Annual Family Income
<15,000
0.02*
24.4
>15,000
27.2
Bodily Pain
None-Mild
25.8
NS
Moderate-Sever
25.1
Years of Education
<12 years
25.2
NS
>12 years
26.4
T-Cell Count
24.9
NS
::::200
26.2
>200
Note: If a :::_0.05 then p- value is significant, NS= Non Significant
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Table. 15:
Multiple T tests with "Behavioral Escape Avoidance"
(Continuous primary I.V.) and other Independent Variables (Categorical)
for people prescribed anti-retroviral medication:
Inde_p_endent Variables
Means
_p_-value
Yrs. of education
<12 yrs.
22.87
NS
21.95
2: 12ES·
Gender
Male
22.4
NS
Female
21.7
Insurance
22.3
None
NS
22.2
Some
Current Health Status
21.8
Good-Excellent
NS
Poor-Fair
23.2
Ethnicity
21.5
Whites
NS
Non-Whites
23.6
Living Arrangement
24.1
0.03*
Alone
21.5
With Others
Annual Family Income
<15,000
22.6
NS
21.7
2:15,000
Bodily Pain
0.01 *
21.2
None-Mild
23.9
Moderate-Sever
Years of Education
<12 years
22.9
NS
>12 years
21.9
T-Cell Count
22.0
NS
:s 200
22.3
>200
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table. 16: Multiple T tests with "Cognitive Escape Avoidance" (Continuous
primary I.V.) and other Independent Variables (Categorical) for people
prescribed anti-retroviral medication:
Independent Variables
Yrs. of education
<12 yrs.
> 12 yrs.
Gender
Male
Female
Insurance
None
Some
Current Health Status
Good-Excellent
Poor-Fair
Ethnicity
Whites
Non-Whites
Living Arrangement
Alone
With Others
Annual Family Income
<15,000
>15,000
Bodily Pain
None-Mild
Moderate-Sever
Years of Education
<12 years
>12 years
T-Cell Count
:::;200
>200

Means

_p_-value

29.2
27.81

NS

27.9
28.8

NS

28.0
28.2

NS

28.2
28.2

NS

27.2
30.2

0.01 *

29.0
27.9

NS

27.8
28.7

NS

28.8
27.3

NS

27.6
29.6

NS

28.3
27.8

NS

Note: If a< 0.05 then p- value is significant, NS= Non Significant
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Table. 17: ANOVA between the categorical I.V's "Time Since Diagnosis",
"age" and continuous primary Independent Variables for people prescribed
An ti-retroviral medication:
R-square
Dependent
F-value
Variable
Time Since Dia_g_nosis
0.03
Seeking social
0.00
SUJ!.l!_Ort
0.00
0.09
Distancin_g_
0.2
0.00
Focusing on
_p_ositive
0.02
1.7
Behavioral escape
avoidance
0.04
2.5
Cognitive escape
avoidance
A_g_e
0.63
0.01
Seeking social
SUJ!.l!_Ort
1.96
0.03
Distancin_g_
2.19
0.03
Focusing on
_Qositive
0.01
0.94
Behavioral escape
avoidance
0.00
0.05
Cognitive escape
avoidance
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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p-value

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

Table. 18: Multiple T tests with "Seeking social support" (Continuous
primary l.V.) and other Independent Variables (Categorical) for people
prescribed Protease-inhibitor medication:
lnd~endent

Variables
Means
1!_-value
Yrs. of education
<12 yrs.
32.75
NS
> 12 yrs.
33.31
Gender
Male
33.4
NS
Female
32.4
Insurance
None
25.3
0.002*
Some
34.2
Current Health Status
Good-Excellent
33.9
NS
Poor-Fair
30.4
Ethnicity
Whites
33.9
NS
Non-Whites
30.6
Living Arrangement
Alone
35.8
NS
With Others
32.2
Annual Family Income
<15,000
33.3
NS
32.4
>15,000
Bodily Pain
None-Mild
31.4
0.03*
Moderate-Sever
35.5
Years of Education
<12 years
32.7
NS
33.3
>12 _years
T-Cell Count
32.8
NS
:s 200
>200
33.4
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table. 19: Multiple T tests with "Distancing" (Continuous primary I.V.) and
other Independent Variables (Categorical) for people prescribed Proteaseinhibitor medication:
Independent Variables
Yrs. of education

Means

_1!_-value

<12 yrs.
> 12_2'.!:_S.

34.58
36.15

NS

36.1
31.3

NS

33.9
39.0

NS

35.8
30.6

NS

33.7
36.2

NS

36.9
33.3

NS

33.6
36.4

NS

31.7
36.4

NS

34.5
34.5

NS

Gender
Male
Female

Insurance
None
Some

Current Health Status
Good-Excellent
Poor-Fair

Ethnicity
Whites
Non-Whites

Living Arrangement
Alone
With Others

Annual Family Income
<15,000
>15,000

Bodily Pain
None-Mild
Moderate-Sever

Years of Education
<12 years
>12 years

T-Cell Count
<200
34.3
>200
34.7
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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NS

Table. 20: Multiple T tests with "Focusing on Positive" (continuous primary
I.V.) and other Independent Variables (Categorical) for people prescribed
Protease-inhibitor medication:
lnde~endent

Variables
Means
_p_-value
Yrs. of education
<12 yrs.
25.93
NS
> 121'.!:_S.
25.82
Gender
Male
26.5
NS
Female
23.7
Insurance
None
21.8
0.04*
26.4
Some
Current Health Status
Good-Excellent
26.4
NS
Poor-Fair
23.4
Ethnicity
Whites
25.7
NS
Non-Whites
26.2
Living Arrangement
Alone
27.5
NS
With Others
25.2
Annual Famil:y Income
<15,000
25.3
NS
>15,000
26.0
Bodil:y Pain
None-Mild
25.5
NS
Moderate-Sever
26.2
Years of Education
<12 years
25.9
NS
>12 years
25.8
T-Cell Count
25.5
NS
:::200
>200
26.1
Note: If a s_0.05 then p- value is significant, NS= Non Significant

\
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Table. 21: Multiple T tests with "Behavioral Escape Avoidance" (Continuous
primary I.V.) and other Independent Variables (Categorical) for people
prescribed Protease-inhibitor medication:
lnde_.l!_endent Variables
Means
_p_-value
Yrs. of education
<12 yrs.
22.5
NS
22.10
2: 12 _2'.!:_S.
Gender
Male
22.5
NS
Female
21.1
Insurance
None
21.5
NS
22.2
Some
Current Health Status
22.0
Good-Excellent
NS
Poor-Fair
22.8
Ethnicity
Whites
21.8
NS
Non-Whites
23.1
Living Arrangement
0.008*
25.0
Alone
21.1
With Others
Annual Family Income
23.1
NS
<15,000
20.9
2:15,000
Bodily Pain
None-Mild
21.3
NS
Moderate-Sever
23.3
Years of Education
22.1
NS
<12 years
22.5
>12 _1'._ears
T-Cell Count
22.2
NS
::::200
>200
21.9
Note: If a .:s_0.05 then p- value is significant, NS= Non Significant
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Table. 22: Multiple T tests with "Cognitive Escape Avoidance" (Continuous
primary I.V.) and other Independent Variables (Categorical) for people
prescribed Protease-inhibitor medication:
lnde_p_endent Variables
Yrs. of education
<12 yrs.
~ 12_.l'.!:_S.
Gender
Male
Female
Insurance
None
Some
Current Health Status
Good-Excellent
Poor-Fair
Ethnicity
Whites
Non-Whites
Living Arrangement
Alone
With Others
Annual Family Income
<15,000

Means

_Q-value

29.23
27.30

NS

27.8
27.1

NS

27.0
27.7

NS

27.9
26.3

NS

27.2
29.5

NS

29.0
27.1

NS

27.2
27.8

NS

~15,000

Bodily Pain
None-Mild
28.2
Moderate-Sever
26.7
Years of Education
<12 years
27.3
29.2
~12 years
T-Cell Count
28.5
:::: 200
>200
26.4
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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NS

NS

NS

Table. 23: ANOVA between the categorical I.V's "Time Since Diagnosis",
"age" and continuous primary Independent Variables for people prescribed
Protease-inhibitor medication:
Dependent
Variable
Time Since Di~nosis
Seeking social
SUHort
Distancin_g_
Focusing on
_p_ositive
Behavioral escape
avoidance
Cognitive escape
avoidance
A_g_e
Seeking social
suHort
Distancin_g_
Focusing on
_p_ositive
Behavioral escape
avoidance
Cognitive escape
avoidance

R-square

F-value

p-value

0.00

0.03

NS

0.00
0.01

0.1
0.5

NS
NS

0.05

2.0

NS

0.1

3.7

0.02*

0.01

0.68

NS

0.06
0.04

2.36
1.72

NS
NS

0.02

0.79

NS

0.00

0.09

NS

Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table. 24: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication With 100% cut off and 'Seeking Social Support'.
Independent
Variables
ssshigh
sssmed

Odds ratio
Point
95% Wald's
estimate
C.I.
0.5
0.1-1.7
0.7
0.2-2.0

Parameter
estimate

Wald's
p-value

-0.5
-0.3

NS
NS

highage
med age

0.5
0.7

0.2-1.6
0.2-2.0

-0.5
-0.2

NS
NS

Health status

0.7

0.2-2.1

-0.3

NS

Ethnicity

0.9

0.3-2.7

-0.004

NS

Education

1.0

0.4-2.6

-0.09

NS

Employment

0.6

0.2-1.6

-0.5

NS

Insurance

0.6

0.1-2.0

-0.4

NS

Income

1.0

0.4-2.4

0.02

NS

Bodily pain

1.9

0.7-5.0

0.6

NS

Longtime
Medtime

1.3
1.6

0.4-4.1
0.4-6.4

0.2
0.5

NS
NS

CD4 count

1.3

0.5-3.3

0.3

NS

Note: If a :::_0.05 then p- value is significant, NS= Non Significant
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Table. 25: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication With 100% cut off and 'Distancing'.
lndependen
t Variables
dishigh
dismed

Odds ratio
Point estimate
95% Wald's
C.I.
0.9
0.3-2.4
0.2-1.9
0.7

Parameter
estimate

Wald's
p-value

-0.09
-0.3

NS
NS

Health
status

0.8

0.2-2.4

-0.2

NS

Education

1.0

0.4-3.5

0.08

NS

Living
arrangement

0.9

0.3-2.3

-0.08

NS

Insurance

0.5

0.1-1.8

-0.5

NS

Income

1.0

0.4-2.5

0.09

NS

Bodily pain

1.3

0.5-3.2

0.2

NS

CD4 count

1.0

0.4-2.3

0.08

NS

Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table. 26: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication With 100% cut off and 'Focusing on Positive'.
Independent
Variables
fop high
fopmed

Odds ratio
Point estimate 95% Wald's
C.I.
0.9
0.3-2.5
1.2
0.4-3.5

Parameter
estimate

Wald's
p-value

-0.03
0.2

NS
NS

Health status

0.8

0.3-2.2

-0.1

NS

Education

1.1

0.5-2.6

0.1

NS

Employment

0.7

0.3-1.7

-0.3

NS

Insurance

0.5

0.1-1.7

-0.5

NS

Income

1.2

0.5-2.7

0.1

NS

Bodily pain

1.1

0.5-2.8

0.1

NS

Note: If a s_0.05 then p- value is significant, NS= Non Significant
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Table. 27: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication With 100% cut off and 'Escape Avoidance
Coping'.
lndependen
t Variables

Odds ratio
Point estimate
95% Wald's
C.I.
With 'Behavioral Escape Avoidance'

Parameter
estimate

Wald's
p-value

beahigh
beamed

0.3
0.1

0.1-0.9
0.05-0.6

-1.1
-1.6

0.04*
0.005*

Education

1.0

0.4-2.6

0.08

NS

Living
arrangement

1.0

0.4-2.5

0.02

NS

Insurance

0.4

0.1-1.3

-0.8

NS

Income

1.1

0.5-2.7

0.1

Bodily pain

1.6

0.6-3.8

0.4

NS

0.3-1.9

-0. l

NS

NS
NS

CD4 count
0.8
With 'Cognitive Escape Avoidance'

NS

ceahigh
ceamed

0.9
0.7

0.3-2.4
0.2-1.9

-0.05
-0.3

Employment

0.7

0.2-1.8

-0.3

NS

Living
arrangement

0.8

0.3-1.8

-0.2

NS

Insurance

0.6

0.2-1.8

-0.4

NS

Income

1.0

0.4-2.3

0.03

NS

Bodily pain

1.2

0.5-2.8

0.2

NS

0.08
0.4-2.4
CD4 count
1.0
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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NS
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Table. 28: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication With 95% cut off and ' Seeking Social Support'.
Independent
Variables
ssshigh
sssmed

Odds ratio
Point estimate 95% Wald ' s
C.I.
1.1
0.2-6.0
0.6
0.1-2.9

Parameter
estimate

Wald' s
p-value

0. 1
-0.4

NS
NS

Gender

0.4

0.1-1.7

-0.7

NS

Ethnicity

0.3

0.07-1.3

-1.1

NS

Education

0.2

0.06-0.8

-1.4

0.02*

Employment

0.2

0.03-1.2

-1.5

NS

Living
arrangement

0.2

0.06-1.0

-1.2

NS

Income

1.4

0.4-5.0

0.3

NS

0.4-5 . l
0.4
1.5
CD4 count
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table. 29 Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication With 95% cut off and 'Distancing'.
Independent
Variables
dishigh
dismed

Odds ratio
Point estimate 95% Wald's
C.I.
1.3
0.2-7.4
0.7
0.1-3.7

Parameter
estimate

Wald's
p-value

0.3
-0.2

NS
NS

Gender

0.5

0.1-1.8

-0.6

NS

Ethnicity

0.4

0.09-1.9

-0.8

NS

Education

0.2

0.08-0.9

-1.2

0.02*

Employment

0.2

0.04-1.4

-1.3

NS

Living
arrangement

0.3

0.08-1.3

-1.1

NS

Income

1.3

0.4-4.6

0.3

NS

CD4 count
1.2
0.3-4.3
0.2
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table. 30 Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication With 95% cut off and 'Focusing on Positive'.
Independent
Variables
Fop high
fop med

Odds ratio
Point estimate 95% Wald's
C.I.
3.7
0.7-20.0
0.4
0.1-1.9

Parameter
estimate

Wald's
p-value

1.3
-0.7

NS
NS

Gender

0.4

0.1-1.6

-0.7

NS

Ethnicity

0.4

0.09-1.7

-0.8

NS

Education

0.2

0.07-0.9

-1.3

0.03*

Employment

0.5

0.09-2.7

-0.6

NS

0.04-0.7
-1.6
Living
0.1
arrang_ement
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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0.02*

Table. 31 Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication With 95% cut off and 'Escape Avoidance
Coping'.
In de pen den
t Variables

Odds ratio
Point estimate
95% Wald's
C.I.
With 'Behavioral Escape Avoidance'

Parameter
estimate

Wald's
p-value

beahigh
beamed

0.1
0.2

0.01-1.8
0.02-2.2

-1.6
-1.4

NS
NS

Gender

0.4

0.1-1.5

-0.8

NS

Ethnicity

0.3

0.07-1.4

-1.1

NS

Education

0.2

0.087-1.0

-1.2

NS

Employment

0.3

0.06-1 .8

-1.0

NS

Living
arrangement

0.4

0.1-1.6

-0.8

NS

0.4-4.8

0.3

NS

CD4 count
1.4
With 'Cognitive Escape Avoidance'
ceahigh
ceamed

0.4
0.2

0.06-2.6
0.03-1.3

-0.8
-1.4

NS
NS

Gender

0.4

0.1-1.6

-0.7

NS

Ethnicity

0.2

0.06-1.1

-1.2

NS

Education

0.2

0.06-0.7

-1.5

NS

Employment

0.2

0.04-1.4

-1.3

NS

Living
arrangement

0.3

0.08-1.1

-1.1

NS

0.5-6.0
CD4 count
1.7
0.5
Note: If a s_0.05 then p- value is significant, NS= Non Significant
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Table. 32 Logistic Regression Analysis between Percentage Adherence to
Protease-inhibitor Medication With 100% cut off and 'Seeking Social
Support'.
lndependen
t Variables
ceahigh
ceamed

Odds ratio
Point estimate 95% Wald's
C.I.
0.8
0.2-3.5
0.9
0.2-4.2

Parameter
estimate

Wald's
p-value

-0.1
-0.003

NS
NS

Gender

0.2

0.05-0.7

-1.6

0.02*

Education

1.2

0.3-4.9

0.3

NS

Insurance

0.4

0.07-2.3

-0.8

NS

Income

0.8

0.2-2.7

-0.1

NS

Bodily pain

0.7

0.2-2.2

-0.2

NS

CD4 count
1.4
0.4-4.2
0.3
Note: If a ::::_0.05 then p- value is significant, NS= Non Significant
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Table. 33 Logistic Regression Analysis between Percentage Adherence to
Protease-inhibitor Medication With 100% cut off and 'Distancing'.
lndependen
t Variables
ceahigh
ceamed

Odds ratio
Point estimate
95% Wald's
C.I.
0.6
0.2-2.3
0.9
0.2-3.6

Parameter
estimate

Wald's
p-value

-0.3
-0.05

NS
NS

Gender

0.2

0.07-0.8

-1.4

0.02*

Ethnicity

1.5

0.4-5.1

0.4

NS

Education

1.4

0.4-5.0

0.3

NS

-0.3
0.2-1.9
Bodily pain
0.7
Note: If a :s._0.05 then p- value is significant, NS= Non Significant
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Table. 34 Logistic Regression Analysis between Percentage Adherence to
Protease-inhibitor Medication With 100% cut off and 'Focusing on Positive' .
Independen
t Variables
ceahigh
ceamed

Odds ratio
Point estimate
95% Wald's
C.I.
0.2
0.06-1.2
0.2
0.06-1.2

Parameter
estimate

Wald's
p-value

-1.2
-1.2

NS
NS

Gender

0.1

0.04-0.7

-1.7

0.01 *

Insurance

0.2

0.05-1.4

-1.3

NS

Income

0.5

0.1-1.9

-0.5

NS

Bodily pain

0.9

0.3-2.7

-0.09

NS

0.4-4.2
CD4 count
0.3
1.5
Note: If a :s._0.05 then p- value is significant, NS= Non Significant

NS
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Table. 35 Logistic Regression Analysis between Percentage Adherence to
Protease-inhibitor Medication With 100% cut off and 'Escape Avoidance
Coping'.
lndependen
t Variables

Odds ratio
Point estimate
95% Wald's
C.I.
With 'Behavioral Escape Avoidance'

Parameter
estimate

Wald's
p-value

ceahigh
ceamed

0.5
0.3

0.1-2.0
0.07-1.6

-0.6
-1.0

NS
NS

Gender

0.1

0.04-0.6

-1.7

0.01 *

Education

1.5

0.4-5.9

0.4

NS

Insurance

0.3

0.06-1.9

-1.0

NS

Bodily pain

0.8

0.2-2.4

-0.l

NS

0.4-3.9

0.3

NS

CD4 count
1.3
With 'Cognitive Escape Avoidance'

(
ceahigh
ceamed

0.6
0.4

0.1-2.6
0.1-1.7

-0.4
-0.7

NS
NS

Gender

0.2

0.05-0.8

-1.5

0.02*

Education

2.0

0.5-8.2

0.7

NS

Insurance

0.5

0.1-3.0

-0.5

NS

Income

0.8

0.2-2.8

-0.1

NS

Bodily pain

0.8

0.2-2.7

-0. l

NS

0.4-4.4
0.3
1.4
CD4 count
Note: If a ~0.05 then p- value is significant, NS= Non Significant
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Table 36.: Logistic Regression Analysis between Percentage Adherence to
Protease-inhibitor Medication With 95% cut off and 'Seeking Social
Support'.
lndependen
t Variables
ssshigh
sssmed

Odds ratio
Point estimate
95% Wald's
C.I.
0.5
0.07-4.8
0.3
0.04-3.6

Parameter
estimate

Wald's
p-value

-0.5
-0.9

NS
NS

Gender

0.1

0.02-0.8

-1.8

0.03*

Education

0.1

0.02-1.0

-1.7

NS

Living
arrangement

0.1

0.02-1.3

-1.8

NS

Bodily pain

0.9

0.1-4.2

-0.1

NS

0.1
CD4 count
1.2
0.2-6.2
Note: If a :::_0.05 then p- value is significant, NS= Non Significant
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Table 37.: Logistic Regression Analysis between Percentage Adherence to
Protease-inhibitor Medication With 95% cut off and 'Focusing on Positive'.
lndependen
t Variables

Odds ratio
Point estimate 95% Wald's

Parameter
estimate

Wald's
p-value

C.I.
fop high
fop med

0.9
0.4

0.1-7.8
0.06-3.6

-0.01
-0.7

NS
NS

Gender

0.1

0.03-0.9

-1.7

0.03*

Education

0.1

0.03-1.1

-1.6

NS

Living
arrangement

0.1

0.01-1.2

-1.9

NS

Bodily pain

0.8

0.1-3 .8

-0.1

NS

0.2-6.2
CD4 count
1.2
0.2
Note: If a :::_0.05 then p- value is significant, NS= Non Significant
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Table 38.: Logistic Regression Analysis between Percentage Adherence to
Protease-inhibitor Medication With 95% cut off and 'Distancing'.
Independen
t Variables
dishigh
dismed

Odds ratio
Point estimate
95% Wald's
C.I.
3.0
0.3-25.3
0.7
0.1-4.7

Parameter
estimate
1.1
-0.3

NS
NS

Gender

0.1

0.02-0.8

-1.9

0.03*

Education

0.1

0.02-0.9

-1.8

0.04*

Living
arrangement

0.1

0.01-0.8

-2.2

0.03*

Bodi!Y.r_ain
0.8
0.1-3.7
-0.1
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table 39.: Logistic Regression Analysis between Percentage Adherence to
Protease-inhibitor Medication With 95% cut off and 'Escape avoidance
coping'.
lndependen
t Variables

Odds ratio
Point estimate 95% Wald's
C.I.
With 'Behavioral Escape Avoidance'

Parameter
estimate

Wald's
p-value

beahigh
beamed

0.3
0.4

0.02-3.6
0.03-6.4

-1.1
-0.7

NS
NS

Gender

0.1

0.03-0.9

-1.7

0.04*

Education

0.2

0.03-1.1

-1.5

NS

Living
arrangement

0.2

0.03-1.6

-1.4

NS

0.2-5.0

0.09

NS

Bodi!YE_ain
1.0
With 'Cognitive Escape Avoidance'
ceahigh
ceamed

1.1
0.8

0.1-9.5
0.1-5.7

0.1
-0.2

NS
NS

Gender

0.1

0.03-0.7

-1.8

0.02*

Education

0.2

0.03-1.7

-1.3

NS

Living
arrangement

0.2

0.03-1.7

-1.4

NS

Bodily pain
0.9
0.2-4.6
-0.02
Note: If a :s_0.05 then p- value is significant, NS= Non Significant

NS
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Table 40.: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication using Medication adherence scale and 'Seeking
Social Support'.
lndependen
t Variables
ssshigh
sssmed

Odds ratio
95% Wald's
Point estimate
C.I.
0.2-1.8
0.6
0.3-2.4
0.9

Parameter
estimate

Wald's
p-value

-0.4
-0.1

NS
NS

highage
medage

0.3
0.9

0.1-1.1
0.3-2.4

-0.9
-0.09

NS
NS

Health
status

0.6

0.2-1.8

-0.4

NS

Education

1.1

0.4-2.8

0.1

NS

Insurance

0.7

0.2-2.5

-0.2

NS

Income

0.6

0.2-1.4

-0.4

NS

Bodily pain

2.2

0.8-5.6

0.7

NS

Longtime
Med time

1.8
1.5

0.5-5.9
0.3-6.1

0.6
0.4

NS
NS

l '

0.9-4.9
0.7
2.1
CD4count
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table 41.: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication using Medication adherence scale and
'Distancing'.
lndependen
t Variables
dishigh
dismed

Odds ratio
Point estimate 95% Wald's
C.I.
0.8
0.3-2.1
0.5
0.2-1.5

Parameter
estimate

Wald's
p-value

-0.2
-0.5

NS
NS

Gender

1.0

0.4-2.6

0.04

NS

Health
status

0.6

0.2-2.1

-0.3

NS

Education

1.2

0.5-3.0

0.2

NS

Insurance

0.7

0.2-2.4

-0.2

NS

Income

0.7

0.3-1.8

-0.2

NS

Bodily pain

1.7

0.7-4.2

0.5

NS

0.8-4.00
0.6
CD4count
1.8
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table 42.: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication using Medication adherence scale and ' Focusing
on Positive'.
lndependen
t Variables
fop high
fop med

Odds ratio
Point estimate
95% Wald ' s
C.I.
0.7
0.2-2.1
0.6
0.2-1.9

Parameter
estimate

Wald's
p-value

-0.2
-0.4

NS
NS

Health
status

0.4

0.1-1.4

-0.7

NS

Living
arrangement

0.5

0.2-1.3

-0.6

NS

Insurance

0.5

0.1-1.8

-0.5

NS

Income

0.7

0.3-1.6

-0.3

NS

Bodily pain

2.2

0.9-5.6

0.8

NS

CD4count
1.4
0.6-3.2
0.4
Note: If a :s_0.05 then p- value is significant, NS= Non Significant
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Table 43.: Logistic Regression Analysis between Percentage Adherence to
Anti-retroviral Medication using Medication adherence scale and 'Escape
Avoidance Coping'.
Independen
t Variables

Odds ratio
Point estimate
95% Wald's
C.I.
With 'Behavioral Escape Avoidance'

Parameter
estimate

Wald's
p-value

beahigh
beamed

0.2
0.1

0.08-0.6
0.06-0.5

-1.4
-1.6

0.005*
0.002*

Income

0.8

0.3-1.9

-0.1

NS

Bodily pain

1.8

0.7-4.2

0.5

NS

0.3-2.6
0.3-4.2

-0.06
0.1

NS
NS

Longtime
0.9
1.1
med time
With ' Cognitive Escape Avoidance '
ceahigh
ceamed

0.7
0.5

0.2-1.9
0.2-1.3

-0.2
-0.6

NS
NS

Living
arrangement

0.5

0.2-1.3

-0.5

NS

Insurance

0.6

0.2-1.9

-0.4

NS

Income

0.7

0.3-1.7

-0.2

NS

Bodily pain

1.6

0.7-3.6

0.4

NS

0.7-3.4
1.5
CD4 count
0.4
Note: If a .:::_0.05 then p- value is significant, NS= Non Significant
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NS
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Table 44.: Logistic Regression Analysis between Percentage Adherence to
Protease inhibitor Medication using Medication adherence scale and
'Seeking Social Support'.
Independen
t Variables
ssshigh
sssmed

Odds ratio
Point estimate
95% Wald's
C.I.
0.7
0.2-2.6
0.3
0.09-1.5

Parameter
estimate

Wald's
p-value

-0.2
-0.9

NS
NS

Health
status

0.4

0.1-1.8

-0.7

NS

Bodily pain

0.9

0.3-2.9

-0.04

NS

1.1-8.5
3.1
1.1
CD4count
Note: If a s_0.05 then p- value is significant, NS= Non Significant

NS
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Table 45.: Logistic Regression Analysis between Percentage Adherence to
Protease inhibitor Medication using Medication adherence scale and
' Distancing'.
Independen
t Variables
dishigh
dismed

Odds ratio
Point estimate 95% Wald' s
C.I.
0.8
0.2-2.7
0.1-1.8
0.4

Parameter
estimate

Wald's
p-value

-0.2
-0.8

NS
NS

Ethnicity

1.7

0.4-6.3

0.5

NS

Education

0.5

0.1-2.2

-0.5

NS

Income

0.3

0.1 -1.0

-1.0

NS

Bodily pain

1.1

0.3-3.3

0.1

NS

1.2
CD4count
3.5
1.1-10.5
Note: If a :::_0.05 then p- value is significant, NS= Non Significant
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Table 46.: Logistic Regression Analysis between Percentage Adherence to
Protease inhibitor Medication using Medication adherence scale and
'Focusing on Positive'.
lndependen
t Variables
fop high
fop med

Odds ratio
Point estimate 95% Wald's
C.I.
0.1-2.7
0.7
0.4
0.09-1.8

Parameter
estimate

Wald's
p-value

-0.3
-0.8

NS
NS

Insurance

0.7

0.1-3.8

-0.2

NS

Income

0.2

0.09-0.9

-1.2

0.03*

Bodily pain

1.1

0.3-3.4

0.1

NS

1.0-8.6
CD4count
3.0
1.1
Note: If a :s._0.05 then p- value is significant, NS= Non Significant
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Table 47.: Logistic Regression Analysis between Percentage Adherence to
Protease inhibitor Medication using Medication adherence scale and
'Escape Avoidance Coping'.
Independent
Variables

Odds ratio
Point estimate 95% Wald's
C.I.
With 'Behavioral Escape Avoidance'

Parameter
estimate

Wald's
p-value

beahigh
beamed

0.6
0.7

0.1-2.3
0.1-3.0

-0.4
-0.2

NS
NS

Health status

0.3

0.08-1.8

-0.9

NS

Education

0.7

0.1-2.9

-0.3

NS

Employment

1.6

0.4-5 .8

0.4

NS

Income

0.3

0.1-1.1

-1.0

NS

Bodily pain

1.1

0.3-3.6

0.1

NS

0.9-8.5

1.0

NS

2.8
CD4count
With 'Cognitive Escape Avoidance'
ceahigh
ceamed

0.6
0.8

0.1-2.4
0.2-3.0

-0.4
-0.2

NS
NS

Insurance

0.9

0.1-4.4

-0.09

NS

Income

0.4

0.1-1.2

-0.8

NS

Bodily pain

1.0

0.3-3.l

0.07

NS

CD4count

3.1

1.0-9.1

1.1

NS

Note: If a s_0.05 then p- value is significant, NS= Non Significant
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APPENDIX II- SAS codes for adherence measures and coping.
(

/*SAS PROGRAM TO DICHOTOMIZE PATIENTS ON ANTIRETROVlRAL DRUGS AS
BEING ADHERENT OR NON ADHERENT BASED ON % CUT OFF DEFINITIONS,
BOTH 100% AND 95 % CUT OFF'S.*/
options nocenter linesize=72;
libname saurabh 'c:\Windows\Desktop\saw-abh';
data saurabh3;
set saurabh.hivsurv;
if qiilx= 'bactrirn' then qii lx2a=O;
if qiilx= 'acyclovir' then qiilx2a=O;
ifqiilx= 'pentamidine' then qiilx2a=O;
if qiilx= 'zoloft' then qiilx2a=O;
ifqiilx= 'crixivan' then qiilx2a=O;
ifqiilx= 'ritonavir' then qiilx2a=O;
if qiilx= 'saquinavir' then qiilx2a=O;
if qii 1x2a=O then qiilx13=.;
ifqiilx13=99 then qiilx2a=.;
if qiilx2a=l then qiilx2a=8;
if qiilx2a=2 then qiilx2a=l2;
ifqiilx2a=3 then qiilx2a=l5;
if qiilx2a=4 then qiilx2a=30;
if qiilx2a=5 then qiilx2a=60;
ifqiilx2a=6 then qiilx2a=90;
ifqiilx2a=7 then qiilx2a=l60;
if qiilx2a=8 then qiilx2a=200;
medl = qiilx13/qiilx2a;
compl =l-medl;
percompl =compl *100;
if qii2x= 'bactrim' then qii2x2a=O;
if qii2x= 'dapsone' then qii2x2a=O;
if qii2x= 'leucovorin' then qii2x2a=O;
if qii2x= 'ms contin' then qii2x2a=O;
if qii2x= 'theodur' then qii2x2a=O;
if qii2x= 'crixivan' then qii2x2a=O;
if qii2x= 'saquinavi.r' then qii2x2a=O;
if qii2x= 'indinavir' then qii2x2a=O;
if qii2x= 'ritonavir' then qii2x2a=O;
if qii2x2a=O then qii2x13 =.;
if qii2x13=99 then qii2x2a=.;
if qii2x2a=l
if qii2x2a=2
if qii2x2a=3
if qii2x2a=4
if qii2x2a=5
if qii2x2a=6
if qii2x2a=7
if qii2x2a=8

then qii2x2a=8;
then qii2x2a=l 2;
then qii2x2a=l 5;
then qii2x2a=30;
then qii2x2a=60;
then qii2x2a=90;
then qii2x2a=160;
then qii2x2a=200;

med2= qii2x13/qii2x2a;
comp2=1-med2;
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percomp2=comp2*100;
if qii3x= 'acyclovir' then qii3x2a=O;
if qii3x= 'bactrim' then qii3x2a=O;
if qii3x= 'biaxin' then qii3x2a=O;
if qii3x= 'clotrimazole' then qii3x2a=O;
if qii3x= 'compazine' then qii3x2a=O;
if qii3x= 'dapsone' then qii3x2a=O;
if qii3x= 'diltiazem' then qii3x2a=O;
if qii3x= 'fluconazole' then qii3x2a=O;
if qii3x= 'mellaril' then qii3x2a=O;
if qii3x= 'minocycline' then qii3x2a=O;
if qii3x= 'motrin' then qii3x2a=O;
if qii3x= 'oxandrin' then qii3x2a=O;
if qii3x= 'vasotec' then qii3x2a=O;
if qii3x= 'zantac' then qii3x2a=O;
if qii3x= 'zovirax' then qii3x2a=O;
if qii3x= 'crixivan' then qii3x2a=O;
if qii3x= 'indinavir' then qii3x2a=O;
if qii3x= 'invirase' then qii3x2a=O;
if qii3x= 'norvir' then qii3x2a=O;
if qii3x= 'ritonavir' then qii3x2a=O;
if qii3x= 'saquinavir' then qii3x2a=O;
if qii3x2a=O then qii3xl3=.;
if qii3x13=99 then qii3x2a=.;
if qii3x2a=l
if qii3x2a=2
if qii3x2a=3
if qii3x2a=4
if qii3x2a=5
if qii3x2a=6
if qii3x2a=7
if qii3x2a=8

then qii3x2a=8;
then qii3x2a=12;
then qii3x2a=15;
then qii3x2a=30;
then qii3x2a=60;
then qii3x2a=90;
then qii3x2a=l 60;
then qii3x2a=200;

med3= qii3x13/qii3x2a;
comp3=1-med3;
percomp3=comp3*100;
ifpercompl=. then percompl=O;
ifpercomp2=. then percomp2=0;
ifpercomp3=. then percomp3=0;
totcomp= percomp 1+percomp2+percomp3;
ifpercompl=O and percomp2 NE 0 and percomp3 NE 0 then totcomp= totcomp/2;
ifpercompl NE 0 and percomp2= 0 and percomp3 NE 0 then totcomp= totcomp/2;
ifpercompl NE 0 and percomp2 NE 0 and percomp3= 0 then totcomp=totcomp/2;
ifpercompl NE 0 and percomp2 NE 0 and percomp3 NE 0 then totcomp=totcomp/3;
ifpercompl NE 0 and percomp2=0 and percomp3= 0 then totcomp= totcomp;
ifpercompl=O and percomp2 NE 0 and percomp3= 0 then totcomp= totcomp;
if percomp 1=O and percomp2=0 and percomp3 NE 0 then totcomp= totcomp;
iftotcomp=O then delete;
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iftotcomp =100 then totcomp=l;
else iftotcomp LT 100 then totcomp=O;
if qvi 1=O then qvi 1=99;
if qvi2=0 then qvi2=99;
if qvi3=0 then qvi3=99;
if qvi4=0 then qvi4=99;
if qvi5=0 then qvi5=99;
if qvi6=0 then qvi6=99;
if qvi7=0 then qvi7=99;
if qvi8=0 then qvi8=99;
if qvi9=0 then qvi9=99;
if qvilO=O then qvi 10=99;
if qvi 11 =O then qvi 11 =99;
if qvi 12=0 then qvi 12=99;
if qvi 13=0 then qvi 13=99;
if qvi14=0 then qvi14=99;
if qvi 15=0 then qvi 15=99;
if qvi 16=0 then qvi 16=99;
if qvi 17=0 then qvi 17=99;
if qvi 18=0 then qvi 18=99;
if qvi 19=0 then qvi 19=99;
if qvi20=0 then qvi20=99;
if qvi21 =O then qvi21 =99;
if qvi22=0 then qvi22=99;
if qvi23=0 then qvi23=99;
if qvi24=0 then qvi24=99;
if qvi25=0 then qvi25=99;
if qvi26=0 then qvi26=99;
if qvi27=0 then qvi27=99;
if qvi28=0 then qvi28=99;
if qvi29=0 then qvi29=99;
if qvi30=0 then qvi30=99;
if qvi31 =O then qvi31 =99;
if qvi32=0 then qvi32=99;
if qvi33=0 then qvi33=99;
if qvi34=0 then qvi34=99;
if qvi35=0 then qvi35=99;
if qvi36=0 then qvi36=99;
if qvi37=0 then qvi37=99;
if qvi38=0 then qvi38=99;
if qvi39=0 then qvi39=99;
if qvi40=0 then qvi40=99;
if qvi41 =O then qvi41 =99;
if qvi42=0 then qvi42=99;
if qvi43=0 then qvi43=99;
if qvi44=0 then qvi44=99;
if qvi45=0 then qvi45=99;
if qvi46=0 then qvi46=99;
if qvi47=0 then qvi47=99;
if qvi48=0 then qvi48=99;
if qvi49=0 then qvi49=99;
if qvi50=0 then qvi50=99;
sss 1=qvi4+qvi34+qvi22+qvi20+qvi16+qvi49+qvi 13+qvi31+qvi6+qvi19+qvi 1;
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dis 1=qvi40+qvi30+qvi33+qvi9+qvi1O+qvil1+qvi50+qvi37+qvi15+qvi32+qvi48+qvi52;
fop 1=qvi26+qvi27+qvi17+qvi41 +qvi21+qvi28+qvi14+qvi4 7;
bea 1=qvi29+qvi23+qvi24+qvi35+qvi39+qvi 18+qvi5+qvi3+qvi25;
cea 1=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi5l+qvi12;
ifsssl GT 149 then sssl=O;
if dis 1 GT 154 then disl =O;
iffopl GT 134 then fopl=O;
ifbeal GT 139 then beal=O;
ifceal GT 139 then ceal=O;
run;

data saurabh7;
set saurabh3;
if qvi 1=99 then qvi 1=O;
if qvi2=99 then qvi2=0;
if qvi3=99 then qvi3=0;
if qvi4=99 then qvi4=0;
if qvi5=99 then qvi5=0;
if qvi6=99 then qvi6=0;
if qvi7=99 then qvi7=0;
if qvi8=99 then qvi8=0;
if qvi9=99 then qvi9=0;
if qvi 10=99 then qvi 1O=O;
if qvil 1=99 then qvil 1=O;
if qvi12=99 then qvi12=0;
if qvi13=99 then qvi13=0;
if qvi14=99 then qvi14=0;
if qvi 15=99 then qvi 15=0;
if qvi 16=99 then qvi 16=0;
if qvi 17=99 then qvi 17=0;
if qvi 18=99 then qvi 18=0;
if qvi 19=99 then qvi 19=0;
if qvi20=99 then qvi20=0;
if qvi21 =99 then qvi21 =O;
if qvi22=99 then qvi22=0;
if qvi23=99 then qvi23=0;
if qvi24=99 then qvi24=0;
if qvi25=99 then qvi25=0;
if qvi26=99 then qvi26=0;
if qvi27=99 then qvi27=0;
if qvi28=99 then qvi28=0;
if qvi29=99 then qvi29=0;
if qvi30=99 then qvi30=0;
if qvi31 =99 then qvi31 =O;
if qvi32=99 then qvi32=0;
if qvi33=99 then qvi33=0;
if qvi34=99 then qvi34=0;
if qvi35=99 then qvi35=0;
if qvi36=99 then qvi36=0;
if qvi37=99 then qvi37=0;
if qvi38=99 then qvi38=0;
if qvi39=99 then qvi39=0;
if qvi40=99 then qvi40=0;
if qvi41 =99 then qvi41 =O;
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if qvi42=99 then qvi42=0;
if qvi43=99 then qvi43=0;
if qvi44=99 then qvi44=0;
if qvi45 =99 then qvi45=0;
if qvi46=99 then qvi46=0;
if qvi47=99 then qvi47=0;
if qvi48=99 then qvi48=0;
if qvi49=99 then qvi49=0;
if qvi50=99 then qvi50=0;
sss=qvi4+qvi34+qvi22+qvi20+qvi 16+qvi49+qvi 13+qvi3 l +qvi6+qvi l 9+qvi 1;
dis=qvi40+qvi30+qvi33+qvi9+qvi 1O+qvi11 +qvi50+qvi37+qvi l 5+qvi32+qvi48+qvi52 ;
fop=qvi26+qvi27+qvil 7+qvi4 l +qvi2l +qvi28+qvi14+qvi47 ;
bea=qvi29+qvi23+qvi24+qvi35+qvi39+qvi l 8+qvi5+qvi3+qvi25 ;
cea=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi5l +qvi12 ;
if sss 1=O then sss=.;
if dis 1=O then dis=.;
if fop 1=O then fop =.;
if beal =O then bea=.;
ifceal =O then cea=.;
label totcomp= 'adherence to AV drugs';
label qil = 'age';
label qi2='gender';
label qi3= 'health status';
label qi4='ethnicity';
label qi5 ='education';
label qi6='employment';
label qi7='living anangement';
label qi18a ='insurance';
label qi19='income';
label qi24='body pain' ;
label qi29='how long ago diagnosed';
label qi31 ='t cell coW1t';
/* new variable 'gender' created*/
gender=.;
if qi2= 'm' then gender=l;
else if qi2= 'f then gender=2;
/* variable age categorized into three categories*/
if qi 1 It 35 then qi 1=3;
else if qi 1 ge 35 and qi 1 le 41 then qi 1=2;
else if qil ge 42 then qil =l;
/* variab le etlrnicity dichotomized to whites or non whites*/
if qi4=0 then qi4=.;
else if qi4=1 then qi4=1;
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0;

I* variable education dichotomized */
if qi5=0 then qi5=.;
else if qi5 It 12 then qi5=1;
else if qi5 ge 12 then qi5=0;
/* variable employment dichotomized */
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if qi6=0 then qi6=.;
else if qi6=1 or qi6=2 then qi6=0;
else if qi6=3 then qi6=1;
/* variable li ving arrangement dichotomized */
if qi7=0 then qi7=.;
else if qi7=1 then qi7=1;
else if qi7=2 then qi7=0 ;
!*variable health status dichotomized */
if qi3=0 then qi3=.;
else if qi3=1 or qi3=2 or qi3 =3 then qi3=0;
else ifqi3=4 or qi3=5 then qi3=1;
!* variab le insurance dichotomized*/
if qil 8a=O then qi! 8a=.;
ifqil8a=2 then qil8a=l;
else if qi l 8a=1 then qil 8a=O;

/* variable income dichotomized*/
if qil9=0 then qil9=.;
else ifqil9=1 thenqil9=1;
else if qil9=2 or qil9=3 or qil9=4 or qil9=5 then qil9=0;

I* variable body pain dichotomized*/
if qi24=0 then qi24=.;
else if qi24=1 or qi24=2 or qi24=3 then qi24=0;
else if qi24=4 or qi24=5 or qi24=6 then qi24=1;
/*variable how long ago diagnosed categorized*/
if qi29=0 then qi29=.;
else if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=3;
else if qi29=5 then qi29=2;
else if qi29=6 then qi29=1;
/* variable T cell count dichotomized*/
if qi31 =O then qi31 =.;
else if qi31 =1 or qi31 =2 then qi31 =O;
else if qi31 = 3 or qi31 =4 then qi31 =1;
sssmed=.;
if sss It 30 or sss ge 37 then sssmed= O;
else if sss ge 30 and sss It 37 then sssmed=l ;
if sss 1=O then sssmed=.;
ssshigh=.;
if sss ge 37 then ssshigh=l ;
else if sss It 37 then ssshigh=O;
if sss 1=O then ssshigh=.;
fop high=.;
if fop GE 29 then fophigh=l;
else if fop LT 29 then fophigh=O;
if fop 1=O then fophigh=. ;
fopmed=.;
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if fop GE 23 and fop LT 29 then fopmed=l;
else if fop GE 29 or fop LT 23 then fopmed=O;
if fop 1=O then fopmed=.;
dishigh=.;
if dis GE 39 then dishigh= l;
else if dis LT 39 then dishigh=O;
if dis 1=Othen dishigh=.;
dismed=.;
if dis GE 33 and dis LT 39 then dismed=l;
else if dis GE 39 or dis LT 33 then dismed=O;
if dis 1=O then dismed=.;
beahigh=.;
ifbea GE 24 then beahigh=l;
else ifbea LT 24 then beahigh=O;
ifbeal =O then beahigh=.;
beamed=.;
ifbea GE 19 and bea LT 24 then beamed=l;
else if bea GE 24 or bea LT 19 then beamed=O;
if bea 1=O then beamed=.;
ceahigh=.;
ifcea GE 31 then ceahigh=l ;
else ifcea LT 31 then ceahigh=O;
if ceal =O then ceahigh=.;
ceamed=.;
if cea GE 25 and cea LT 31 then ceamed=l;
else ifcea GE 31 or cea LT 25 then ceamed=O;
ifceal =O then ceamed=.;
proc format;
value adherence 1= 'adl1erent'
O= 'nonadherent';
proc univariate normal plot;
var qil qi3 qi4 qi5 qi6 qi7 qi18a qi19
qi24 qi29 qi31;
proc freq;
tables totcomp qil qi2 qi3 qi4 qi5 qi6 qi7 qil 8a qi19
qi24 qi29 qi31 ssshigh sssmed;
format totcomp adherence.;
proc logistic descending;
model totcomp= ssshigh sssmed qil gender qi3 qi4 qi5 qi6 qi7 qi18a qi19
qi24 qi29 qi31 / ctable pprob= (0 to 1 by .1 ) lackfit risklimits; run ;
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/* SAS PROGRAM TO DICHOTOMIZE PATI ENTS ON ANTIRETROVIRAL DRUGS AS
BEING ADH ERE NT OR NON ADHERENT
BASE D ON MEDICATION ADH ERENCE SCALE.*/
options nocenter linesize=72;
libname saurabh 'c:\Documents and Settings\Erabus\DESKTOP\saurabb';
data saurabh3 ;
set saurabh.hivsurv;
if qiilx4=0 then qiilx4=99;
if qiilx5=0 then qiilx5=99;
if qiilx6=0 then qiilx6=99;
if qii 1x7=0 then qii 1x7=99;
if qiilx8=0 then qiilx8=99;
ifqiilx9=0 then qiilx9=99;
if qii2x4=0 then qii2x4=99;
if qii2x5=0 then qii2x5=99;
if qii2x6=0 then qii2x6=99;
if qii2x7=0 then qii2x7=99;
if qii2x8=0 then qii2x8=99;
if qii2x9=0 then qii2x9=99;
if qii3x4=0 then qii3x4=99;
if qii3x5=0 then qii3x5=99;
if qii3x6=0 then qii3x6=99;
if qii3x7=0 then qii3x7=99;
if qii3x8=0 then qii3x8=99;
if qii3x9=0 then qii3x9=99;
maslx= qiilx4+qii lx5 +qii lx6+qiilx7+qii 1x8+qii1 x9;
ifmasl GE 109 then masl =O;
mas2x= qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9;
ifmas2x GE 109 then mas2=0;
mas3x= qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9;
ifmas3x GE 109 then mas3=0;
data saurabh6;
set saurabh3 ;
if qiilx4=99 then qiilx4=0;
if qiilx5=99 then qiilx5=0;
if qiilx6=99 then qiilx6=0;
if qii I x7=99 then qii 1x7=0;
ifqiilx8=99 then qiilx8=0;
ifqiilx9=99 then qiilx9=0;
mas I =qii I x4+qii I x5 +qii I x6+qii I x7+qii lx8+qii 1x9;
if mas I x=O then mas 1=O;
if qii2x4=99 then qii2x4=0;
if qii2x5=99 then qii2x5=0;
if qii2x6=99 then qii2x6=0;
if qii2x7=99 then qii2x7=0;
if qii2x8=99 then qii2x8=0;
if qii2x9=99 then qii2x9=0;
mas2=qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9;

110

ifmas2x=O then mas2=0;
if qii3x4=99 then qii3x4=0;
if qii3x5=99 then qii3x5=0;
if qii3x6=99 then qii3x6=0;
if qii3x7=99 then qii3x7=0;
if qii3x8=99 then qii3x8=0;
if qii3x9=99 then qii3x9=0;
mas3=qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9;
if mas3x=O then mas3=0;
ifqiilx= 'bactrim' then masl=O;
if qiilx= 'acyclovir' then masl=O;
if qii 1x= 'pentamidine' then mas 1=O;
if qii 1x= 'zoloft' then mas 1=O;
if qii 1x= 'crixivan' then mas 1=O;
if qiilx= 'ritonavir' then masl=O;
if qii 1x= 'saquinavir' then mas 1=O;
if qii2x= 'bactrim' then mas2=0;
if qii2x= 'dapsone' then mas2=0;
if qii2x= 'leucovorin' then mas2=0;
if qii2x= 'ms contin' then mas2=0;
if qii2x= 'theodur' then mas2=0;
if qii2x= 'crixivan' then mas2=0;
if qii2x= 'saquinavir' then mas2=0;
if qii2x= 'indinavir' then mas2=0;
if qii2x= 'ritonavir' then mas2=0;
if qii3x= 'acyclovir' then mas3=0;
if qii3x= 'bactrin1' then mas3=0;
if qii3x= 'biaxin' then mas3=0;
if qii3x= 'clotTirnazole' then mas3=0;
if qii3x= 'compazine' then mas3=0;
if qii3x= 'dapsone' then mas3=0;
if qii3x= 'diltiazem' then mas3=0;
if qii3x= 'fluconazole' then mas3=0;
if qii3x= 'mellaril' then mas3=0;
if qii3x= 'minocycline' then mas3=0;
if qii3x= 'motrin' then mas3=0;
if qii3x= 'oxandrin' then mas3=0;
if qii3x= 'vasotec' then mas3=0;
if qii3x= 'zantac' then mas3=0;
if qii3x= 'zovirax' then mas3=0;
if qii3x= 'crixivan' then mas3=0;
if qii3x= 'indinavir' then mas3=0;
if qii3x= 'invirase' then mas3=0;
if qii3x= 'norvir' then mas3=0;
if qii3x= 'ritonavir' then mas3=0;
if qii3x= 'saquinavir' then mas3=0;
totmas=mas 1+mas2+mas3 ;
ifmasl NE 0 and mas2 NE 0 and mas3 NE 0 then totmas= totmas/3 ;
ifmasl NE 0 and mas2= 0 and mas3 NE 0 then totmas= totmas/2;
ifmasl =O and mas2 NE 0 and mas3 NE 0 then totmas= totmas/2;
ifmasl NE 0 and mas2 NE 0 and mas3=0 then totmas= totmas/2;
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ifmasl NE 0 and rnas2=0 and mas3=0 then totrnas=totrnas;
ifmasl=O and mas2 NE 0 and mas3=0 then totrnas=totrnas;
ifrnasl=O and mas2=0 and mas3 NE 0 then totrnas=totrnas;
iftotrnas LT 6 then delete;
totrnas 1=12-totrnas;
if totrnas 1 =6 then totrnas 1=I;
else iftotrnasl LT 6 then totrnasl=O;
if qvi 1=O then qvi 1=99;
if qvi2=0 then qvi2=99;
if qvi3=0 then qvi3=99;
if qvi4=0 then qvi4=99;
if qvi5=0 then qvi5=99;
if qvi6=0 then qvi6=99;
if qvi7=0 then qvi7=99;
if qvi8=0 then qvi8=99;
if qvi9=0 then qvi9=99;
if qvilO=O then qvi10=99;
if qvil 1=0 then qvil 1=99;
if qvil2=0 then qvi12=99;
if qvi 13=0 then qvi 13=99;
if qvi 14=0 then qvi 14=99;
ifqvil5=0 then qvil5=99;
if qvil6=0 then qvil6=99;
if qvil 7=0 then qvil 7=99;
if qvi 18=0 then qvi 18=99;
if qvi 19=0 then qvi 19=99;
if qvi20=0 then qvi20=99;
if qvi2 l =O then qvi2 l =99;
if qvi22=0 then qvi22=99;
if qvi23=0 then qvi23=99;
if qvi24=0 then qvi24=99;
if qvi25=0 then qvi25=99;
if qvi26=0 then qvi26=99;
if qvi27=0 then qvi27=99;
if qvi28=0 then qvi28=99;
if qvi29=0 then qvi29=99;
if qvi30=0 then qvi30=99;
if qvi3 l =O then qvi3 l =99;
if qvi32=0 then qvi32=99;
if qvi33=0 then qvi33=99;
if qvi34=0 then qvi34=99;
if qvi35=0 then qvi35=99;
if qvi36=0 then qvi36=99;
if qvi37=0 then qvi37=99;
if qvi38=0 then qvi38=99;
if qvi39=0 then qvi39=99;
if qvi40=0 then qvi40=99;
if qvi4 l =O then qvi4 l =99;
if qvi42=0 then qvi42=99;
if qvi43=0 then qvi43=99;
if qvi44=0 then qvi44=99;
if qvi45=0 then qvi45=99;
if qvi46=0 then qvi46=99;
if qvi4 7=0 then qvi4 7=99;
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if qvi48=0 then qvi48=99;
if qvi49=0 then qvi49=99;
if qvi50=0 then qvi50=99;

sss 1=qvi4+qvi34+qvi22+qvi20+qvi16+qvi49+qvi 13+qvi31+qvi6+qvi19+qvil;
dis 1=qvi40+qvi30+qvi33+qvi9+qvi1O+qvil1+qvi50+qvi37+qvil5+qvi32+qvi48+qvi52;
fop 1=qvi26+qvi27+qvi17+qvi41 +qvi21+qvi28+qvil4+qvi4 7;
bea 1=qvi29+qvi23+qvi24+qvi35+qvi39+qvi18+qvi5+qvi3+qvi25;
cea 1=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi51+qvi12;
ifsssl GT 149 then sssl=O;
if dis 1 GT 154 then dis 1=O;
iffopl GT 134 then fopl=O;
ifbeal GT 139 then beal=O;
ifceal GT 139 then ceal=O;
run;

data saurabh7;
set saurabh6;
if qvi 1=99 then qvi 1=O;
if qvi2=99 then qvi2=0;
if qvi3=99 then qvi3=0;
if qvi4=99 then qvi4=0;
if qvi5=99 then qvi5=0;
if qvi6=99 then qvi6=0;
if qvi7=99 then qvi7=0;
if qvi8=99 then qvi8=0;
if qvi9=99 then qvi9=0;
if qvi 10=99 then qvi 10=0;
if qvi 11 =99 then qvi 11 =O;
if qvi 12=99 then qvi 12=0;
if qvi 13=99 then qvi 13=0;
if qvi14=99 then qvi14=0;
if qvi15=99 then qvi15=0;
if qvi16=99 then qvil6=0;
if qvi 17=99 then qvi 17=0;
if qvi 18=99 then qvi 18=0;
if qvi 19=99 then qvi 19=0;
if qvi20=99 then qvi20=0;
if qvi21 =99 then qvi21 =O;
if qvi22=99 then qvi22=0;
if qvi23=99 then qvi23=0;
if qvi24=99 then qvi24=0;
if qvi25=99 then qvi25=0;
if qvi26=99 then qvi26=0;
if qvi27=99 then qvi27=0;
if qvi28=99 then qvi28=0;
if qvi29=99 then qvi29=0;
if qvi30=99 then qvi30=0;
if qvi31 =99 then qvi31 =O;
if qvi32=99 then qvi32=0;
if qvi33=99 then qvi33=0;
if qvi34=99 then qvi34=0;
if qvi35=99 then qvi35=0;
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if qvi36=99 then qvi36=0;
if qvi37=99 then qvi37=0;
if qvi38=99 then qvi38=0;
if qvi39=99 then qvi39=0;
if qvi40=99 then qvi40=0;
if qvi41 =99 then qvi41 =O;
if qvi42=99 then qvi42=0;
if qvi43=99 then qvi43=0;
if qvi44=99 then qvi44=0;
if qvi45=99 then qvi45=0;
if qvi46=99 then qvi46=0;
ifqvi47=99 then qvi47=0;
if qvi48=99 then qvi48=0;
if qvi49=99 then qvi49=0;
if qvi50=99 then qvi50=0;
sss=qvi4+qvi34+qvi22+qvi20+qvi 16+qvi49+qvi l 3+qvi31+qvi6+qvi19+qvi 1;
dis=qvi40+qvi30+qvi33+qvi9+qvi 1O+qvi11 +qvi50+qvi37+qvi 15+qvi32+qvi48+qvi52;
fop=qvi26+qvi27+qvi l 7+qvi41 +qvi21+qvi28+qvil4+qvi4 7;
bea=qvi29+qvi23+qvi24+qvi35+qvi39+qvi18+qvi5+qvi3+qvi25;
cea=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi51 +qvi12;
if sss 1=O then sss=.;
if dis 1=O then dis=.;
iffopl=O then fop=.;
ifbeal=O then bea=.;
if cea 1=O then cea=.;
label totmasl = 'adherence to AV dmgs';
label qi 1= 'age';
label qi2='gender';
label qi3= 'health status';
label qi4='ethnicity';
label qi5='education';
label qi6='employment';
label qi7='l iving arrangement';
label qi 18a ='insurance';
label qi19='income';
label qi24='body pain';
label qi29='how long ago diagnosed';
label qi31='t cell cow1t';
/*new variable 'gender' created*/
gender=.;
if qi2= 'm' then gender=!;
else if qi2= 'f then gender=2;
/* variable age categorized into three categories*/
ifqil lt35thenqi1 =3;
else if qil ge 35 and qi 1 le 41 then qi 1=2 ;
else if qi 1 ge 42 then qil =I;
/* variable ethnicity dichotomized to whites or non whites*/
if qi4=0 then qi4=.;
else ifqi4=1 then qi4=1;
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0 ;
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/* va1iable education dichotomized*/
if qi5=0 then qi5=.;
else if qi5 It 12 then qi5=1;
else if qi5 ge 12 then qi5=0;
/* variable employment dichotomized*/
if qi6=0 then qi6=.;
else if qi6=1 or qi6=2 then qi6=0;
else if qi6=3 then qi6=1;

I* variab le liviug arrangement dichotomized */
if qi7=0 then qi7=.;
else if qi7=1 then qi7=1;
else if qi7=2 then qi7=0;
I* variable health status dichotomized */
if qi3 =0 then qi3=.;
else if qi3=1 or qi3=2 or qi3=3 then qi3=0 ;
else if qi3=4 or qi3=5 then qi3=1;
!* variable insurance dichotomized */
ifqi18a=O then qi18a=.;
ifqi18a=2 then qi18a= l ;
else ifqi18a=l thenqi18a=O;
I* variable income dichotomized*/
if qi 19=0 then qi 19=. ;
else if qi 19=1 then qi 19=1;
else if qi19=2 or qil9=3 or qi19=4 or qil9=5 then qi19=0 ;

/* variable body pain dichotomized*/
if qi24=0 then qi24=.;
else if qi24=1 or qi24=2 or qi24=3 then qi24=0;
else if qi24=4 or qi24=5 or qi24=6 then qi24=1;
/* va1iable how long ago diagnosed categorized*/
if qi29=0 then qi29=.;
else if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=3;
else if qi29=5 then qi29=2 ;
else if qi29=6 then qi29=1;

I* va1iab le T cell cow1t dichotomized*/
if qi31 =O then qi31 =.;
else if qi31 = 1 or qi31 =2 then qi31 =O;
else if qi31 = 3 or qi31 =4 then qi31 =1;
sssmed=.;
if sss It 30 or sss ge 37 then sssmed= O;
else if sss ge 30 and sss It 37 then sssmed=l;
if sss 1=O then sssmed=.;
ssshigh=.;
if sss ge 37 then ssshigh=l ;
else if sss It 37 then ssshigh=O;
if sss 1=O then ssshigh=.;
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fophigh=.;
if fop GE 29 then fophigh=l ;
else if fop LT 29 then fophigh=O;
if fop 1=O then fophigh=.;
fopmed=.;
if fop GE 22 and fop LT 29 then fopmed=l;
else if fop GE 29 or fop LT 22 then fopmed=O;
iffopl =O then fopmed=.;
dishigh=.;
if dis GE 39 then dishigh=l;
else if dis LT 39 then dishigh=O;
if dis 1=O then dishigh=.;
dismed=.;
if dis GE 33 and dis LT 39 then dismed=l;
else if dis GE 39 or dis LT 33 then dismed=O;
if dis 1=O then dismed=.;
beahigh=.;
if bea GE 24 then beahigh=l;
else ifbea LT 24 then beahigh=O;
ifbeal =O then beahigh=.;
beamed=.;
ifbea GE 19 and bea LT 24 then beamed=l;
else ifbea GE 24 or bea LT 19 then beamed=O;
if bea 1=O then beamed=.;
ceahigh=.;
ifcea GE 31 then ceahigh=l;
else ifcea LT 31 then ceahigh=O;
if cea 1=O then ceahigh=.;
ceamed=.;
ifcea GE 25 and cea LT 31 then ceamed=l;
else ifcea GE 31 or cea LT 25 then ceamed=O;
if cea 1=O then ceamed=.;
proc format ;
value adherence 1= 'adJ1erent'
O= 'nonadherent';
proc univariate normal plot;
var qil qi3 qi4 qi5 qi6 qi7 qil8a qi19
qi24 qi29 qi3 l;
proc freq ;
tables totmasl qil qi2 qi3 qi4 qi5 qi6 qi7 qi18a qi19
qi24 qi29 qi31 ssshigh sssmed;
format totmasl adherence.;
proc logistic descending;
model totmasl = ssshigh sssmed qil gender qi3 qi4 qi5 qi6 qi7 qil8a qi19
qi24 qi29 qi31 / ctable pprob= (0 to 1 by .1) lackfit risklimits; run ;
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/*SAS PROGRAM TO DICHOTOMIZE PATIENTS ON PROTEASE INHIBITOR
DRUGS AS BEING ADHERENT OR NON ADHERENT BASED ON PERCENT AGE
ADHERENCE DEFINITIONS.*/
options nocenter linesize=72;
libname saurabh 'c:\Documents and Settings\Erabus\DESKTOP\saurabh';
data saurabh3;
set saurabh.hivsurv;
ifqiilx= 'bactrim' then qiilx2a=O;
if qiilx= 'acyclovir' then qiilx2a=O;
if qiilx= 'pentam.idine' then qiilx2a=O;
if qiilx= 'zoloft' then qii lx2a=O;
if qiilx= '3tc' then qiilx2a=O;
ifqiilx= 'azt' then qiilx2a=O;
if qiilx= 'd4t' then qiilx2a=O;
ifqiilx= 'ddc' then qiilx2a=O;
ifqiilx= 'ddi' then qiilx2a=O;
if qiilx= 'zerit' then qiilx2a=O;
if qiilx= 'epivir' then qiilxla=O;
if qiilx2a=O then qiilx13=.;
ifqiilx13=99 then qiilx2a=.;
if qiilx2a=l then qiilx2a=8;
if qiilx2a=2 then qii lx2a=l2;
if qiilx2a=3 then qiilx2a=l5;
if qiilx2a=4 then qiilx2a=30;
if qiilx2a=S then qiilx2a=60;
if qiilx2a=6 then qiilx2a=90;
if qiilx2a=7 then qiilx2a=160;
ifqiilx2a=8 then qiilx2a=200;
medl= qiilx13/qiilx2a;
compl=l-medl;
percompl=compl *100;
if qii2x= 'bactrim' then qii2x2a=O;
if qii2x= 'dapsone' then qii2x2a=O;
if qii2x= 'leucovorin' then qii2x2a=O;
if qii2x= 'ms contin' then qii2x2a=O;
if qii2x= 'theodur' then qii2x2a=O;
if qii2x= '3tc' then qii2x2a=O;
if qii2x= 'azt' then qii2x2a=O;
if qii2x= 'd4t' then qii2x2a=O;
if qii2x= 'ddc' then qii2x2a=O;
if qii2x= 'ddi' then qii2x2a=O;
if qii2x= 'epivir' then qii2x2a=O;
if qii2x= 'zerit' then qii2x2a=O;
if qii2x2a=O then qii2x13=.;
if qii2x13=99 then qii2x2a=.;
if qii2x2a=1 then qii2x2a=8;
if qii2x2a=2 then qii2x2a=l2;
if qii2x2a=3 then qii2x2a=l5;
if qii2x2a=4 then qii2x2a=30;
if qii2x2a=S then qii2x2a=60;
if qii2x2a=6 then qii2x2a=90;
if qii2x2a=7 then qii2x2a=l60;
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if qii2x2a=8 then qii2x2a=200;

(
med2= qii2xl3/qii2x2a;
comp2=1-med2;
percomp2=comp2*100;
if qii3x= 'acyclovir' then qii3x2a=O;
if qii3x= 'bactrim' then qii3x2a=O;
if qii3x= 'biaxi11' then qii3x2a=O;
if qii3x= 'clotrimazole' then qii3x2a=O;
if qii3x= 'compazine' then qii3x2a=O;
if qii3x= 'dapsone' then qii3x2a=O;
if qii3x= 'diltiazem' then qii3x2a=O;
if qii3x= 'fluconazole' then qii3x2a=O;
if qii3x= 'mellaril' then qii3x2a=O;
if qii3x= 'minocycline' then qii3x2a=O;
if qii3x= 'motrin' then qii3x2a=O;
if qii3x= 'oxanclrin' then qii3x2a=O;
if qii3x= 'vasotec' then qii3x2a=O;
if qii3x= 'zantac' then qii3x2a=O;
if qii3x= 'zovirax' then qii3x2a=O;
if qiilx= 'azt' then qiilx2a=O;
if qiilx= '3tc' then qiilx2a=O;
ifqiilx= 'd4t' then qiilx2a=O;
ifqiilx= 'epivir' then qiilx2a=O;
ifqii3x2a=O then qii3xl3=.;
if qii3x13=99 then qii3x2a=.;
if qii3x2a=l
if qii3x2a=2
if qii3x2a=3
if qii3x2a=4
if qii3x2a=5
if qii3x2a=6
if qii3x2a=7
if qii3x2a=8

then qii3x2a=8;
then qii3x2a=l2;
then qii3x2a=l5;
then qii3x2a=30;
then qii3x2a=60;
then qii3x2a=90;
then qii3x2a=l 60;
then qii3x2a=200;

med3= qii3x13/qii3x2a;
comp3=1-med3;
percomp3=comp3*100;
if percomp 1=. then percomp 1=O;
if percomp2=. then percomp2=0;
ifpercomp3=. then percomp3=0;
totcomp= percomp 1+percomp2+percomp3;
ifpercompl=O and percomp2 NE 0 and percomp3 NE 0 then totcomp= totcomp/2;
ifpercompl NE 0 and percomp2= 0 and percomp3 NE 0 then totcomp= totcomp/2;
ifpercompl NE 0 and percomp2 NE 0 and percomp3= 0 then totcomp=totcomp/2;
ifpercompl NE 0 and percomp2 NE 0 and percomp3 NE 0 then totcomp=totcomp/3;
if percomp 1 NE 0 and percomp2=0 and percomp3= 0 then totcomp= totcomp;
ifpercompl=O and percomp2 NE 0 and percomp3= 0 then totcomp= totcomp;
ifpercompl=O and percomp2=0 and percomp3 NE 0 then totcomp= totcomp;
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if totcomp=O then delete;
if totcomp =100 then totcomp=l;
else if totcomp LT 100 then totcomp=O;
if qvil =O then qvil =99;
if qvi2=0 then qvi2=99;
if qvi3=0 then qvi3=99;
if qvi4=0 then qvi4=99;
if qvi5=0 then qvi5=99;
if qvi6=0 then qvi6=99;
if qvi7=0 then qvi7=99;
if qvi8=0 then qvi8=99;
if qvi9=0 then qvi9=99;
if qvilO=O then qvil0=99;
if qvi 11 =O then qvi 11 =99;
if qvil2=0 then qvil2=99;
if qvi 13=0 then qvi 13=99;
if qvi 14=0 then qvi 14=99;
if qvil5=0 then qvil5=99;
if qvi 16=0 then qvi 16=99;
if qvi 17=0 then qvi 17=99;
if qvi 18=0 then qvi 18=99;
if qvi 19=0 then qvi 19=99;
if qvi20=0 then qvi20=99;
if qvi2 l =O then qvi2 l =99;
if qvi22=0 then qvi22=99;
if qvi23=0 then qvi23=99;
if qvi24=0 then qvi24=99;
if qvi25=0 then qvi25=99;
if qvi26=0 then qvi26=99;
if qvi27=0 then qvi27=99;
if qvi28=0 then qvi28=99;
if qvi29=0 then qvi29=99;
if qvi30=0 then qvi30=99;
if qvi3 l =O then qvi3 l =99;
if qvi32=0 then qvi32=99;
if qvi33=0 then qvi33=99;
if qvi34=0 then qvi34=99;
if qvi35=0 then qvi35=99;
if qvi36=0 then qvi36=99;
if qvi37=0 then qvi37=99;
if qvi38=0 then qvi38=99;
if qvi39=0 then qvi39=99;
if qvi40=0 then qvi40=99;
if qvi4 l =O then qvi4 l =99;
if qvi42=0 then qvi42=99;
if qvi43=0 then qvi43=99;
if qvi44=0 then qvi44=99;
if qvi45=0 then qvi45=99;
if qvi46=0 then qvi46=99;
if qvi47=0 then qvi47=99;
if qvi48=0 then qvi48=99;
if qvi49=0 then qvi49=99;
if qvi50=0 then qvi50=99;
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sss 1=qvi4+qvi34+qvi22+qvi20+qvi16+qvi49+qvi 13+qvi31+qvi6+qvi19+qvi 1;
dis 1=qvi40+qvi30+qvi33+qvi9+qvi1O+qvi11+qvi50+qvi37+qvil5+qvi32+qvi48+qvi52;
fopl =qvi26+qvi27+qvil 7+qvi41 +qvi21 +qvi28+qvi14+qvi47;
bea 1=qvi29+qvi23+qvi24+qvi35+qvi39+qvi18+qvi5+qvi3+qvi25;
cea 1=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi51+qvi12;
ifsssl GT 149 then sssl=O;
ifdisl GT 154 then disl=O;
iffopl GT 134 then fopl=O;
ifbeal GT 139 then beal=O;
ifceal GT 139 then ceal=O;
run;
data saurabh7;
set saurabh3;

if qvi 1=99 then qvi 1=O;
if qvi2=99 then qvi2=0;
if qvi3=99 then qvi3=0;
if qvi4=99 then qvi4=0;
if qvi5=99 then qvi5=0;
if qvi6=99 then qvi6=0;
if qvi7=99 then qvi7=0;
if qvi8=99 then qvi8=0;
if qvi9=99 then qvi9=0;
if qvi 10=99 then qvi 1O=O;
if qvi 11 =99 then qvi 11 =O;
if qvi 12=99 then qvi 12=0;
if qvi 13=99 then qvi 13=0;
if qvi 14=99 then qvi 14=0;
if qvi 15=99 then qvi 15=0;
if qvi 16=99 then qvil 6=0;
ifqvi17=99 then qvi17=0;
if qvi 18=99 then qvi 18=0;
if qvi 19=99 then qvi 19=0;
if qvi20=99 then qvi20=0;
if qvi21 =99 then qvi21 =O;
if qvi22=99 then qvi22=0;
if qvi23=99 then qvi23=0;
if qvi24=99 then qvi24=0;
if qvi25=99 then qvi25=0;
if qvi26=99 then qvi26=0;
if qvi27=99 then qvi27=0;
if qvi28=99 then qvi28=0;
if qvi29=99 then qvi29=0;
if qvi30=99 then qvi30=0;
if qvi31 =99 then qvi31 =O;
if qvi32=99 then qvi32=0;
if qvi33=99 then qvi33=0;
if qvi34=99 then qvi34=0;
if qvi35=99 then qvi35=0;
if qvi36=99 then qvi36=0;
if qvi37=99 then qvi37=0;
if qvi38=99 then qvi38=0;
if qvi39=99 then qvi39=0;
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if qvi40=99 then qvi40=0;
if qvi4 I =99 then qvi4 I =O;
if qvi42=99 then qvi42=0;
if qvi43=99 then qvi43=0;
if qvi44=99 then qvi44=0;
if qvi45=99 then qvi45=0;
if qvi46=99 then qvi46=0;
if qvi47=99 then qvi47=0;
if qvi48=99 then qvi48=0;
if qvi49=99 then qvi49=0;
if qvi50=99 then qvi50=0;
sss=qvi4+qvi34+qvi22+qvi20+qvi I 6+qvi49+qvi I 3+qvi3 I +qvi6+qvi I 9+qvi I;
dis=qvi40+qvi30+qvi33+qvi9+qvi I O+qvi I I +qvi50+qvi37+qviI 5+qvi32+qvi48+qvi52;
fop=qvi26+qvi2 7+qvi I 7+qvi4 I +qvi2 I +qvi28+qvi I 4+qvi4 7;
bea=qvi29+qvi23+qvi24+qvi3 5+qvi3 9+qvi I 8+qvi5+qvi3+q vi2 5;
cea=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi5 I +qviI2;
if sss I =O then sss=.;
if dis I =O then dis=.;
iffopI=O then fop=.;
ifbeaI=O then bea=.;
if cea I =O tl1en cea=.;
label totmasI ='adherence to AV drugs';
label qi I= 'age';
label qi2='gender';
label qi3= 'health status';
label qi4='ethnicity';
label qi5='education';
label qi6='employment';
label qi7='1iving aITangement';
label qiI 8a ='insurance';
label qiI9='income';
label qi24='body pain';
label qi29='how long ago diagnosed';
label qi3 I ='t cell count';

I* new variable 'gender' created*/
gender=.;
if qi2= 'm' then gender= I;
else if qi2= 'f then gender=2;
I* variable age categorized into three categories*/
if qi I It 35 then qi I =3;
else ifqiI ge 35 and qiI le 41 then qiI=2;
else if qi I ge 42 then qiI=l;
I* variable ethnicity dichotomized to whites or non whites*/
if qi4=0 then qi4=.;
else if qi4=1 ilien qi4=1;
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 ilien qi4=0;
I* variable education dichotomized */
if qi5=0 then qi5=.;
else if qi5 It 12 ilien qi5=1;
else if qi5 ge 12 then qi5=0 ;

121

/* varia ble employment dichotomized*/
if qi6=0 then qi6=.;
else if qi6=1 or qi6=2 then qi6=0;
else if qi6=3 then qi6=1;
/* variable living arrangement dichotomized */
if qi7=0 then qi7=.;
else if qi7=1 then qi7=1;
else if qi7=2 then qi7=0;
I* variable health status dichotomized */

if qi3=0 then qi3=.;
else if qi3=1 or qi3 =2 or qi3=3 then qi3=0;
else if qi3=4 or qi3=5 then qi3=1;
/* variable insw-ance dichotomized */
ifqi18a=O then qi18a=.;
if qi 18a=2 then qi 18a= 1;
else ifqi18a=1 then qi18a=O ;
I* variable income dichotomized */

ifqi19=0 then qil9=.;
else ifqi19=1 then qi19=1;
else ifqi19=2 or qi19=3 or qil9=4 or qi19=5 then qi19=0;

I* variable body pai11 dichotomized */
if qi.24=0 then qi24=.;
else if qi24=1 or qi24=2 or qi.24=3 then qi24=0;
else if qi24=4 or qi24=5 or qi.24=6 then qi24=1;

/* variable how long ago diagnosed categorized*/
if qi29=0 then qi29=.;
else if qi29= 1 or qi.29=2 or qi.29=3 or qi.29=4 then qi29=3;
else if qi29=5 then qi.29=2;
else if qi29=6 then qi29=1;
/* variable T cell count dichotomized*/
ifqi31=0 then qi31 =.;
else if qi31 = 1 or qi31 =2 then qi31 =O;
else if qi31 =3 or qi.31 =4 then qi31 =l;
sssmed=.;
if sss lt 29 or sss ge 35 then sssmed= O;
else if sss ge 29 and sss lt 35 then sssmed=l;
if sss 1=O then sssmed=.;
ssshigh=.;
if sss ge 35 then ssshigh=l;
else if sss lt 35 then ssshigh=O;
if sss 1=O then ssshigh=.;
fophigh=.;
if fop GE 29 then fophigh=l;
else if fop LT 29 then fophigh=O;
iffopl =O then fophigh=.;
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fopmed=.;
if fop GE 23 and fop LT 29 then fopmed=l;
else if fop GE 29 or fop LT 23 then fopmed=O;
if fop 1=O then fopmed=.;
dishigh=.;
if dis GE 39 then dishigh=l;
else if dis LT 39 then dishigh=O;
if dis 1=O then dishigh=.;
dismed=.;
if dis GE 33 and dis LT 39 then dismed=l;
else if dis GE 39 or dis LT 33 then dismed=O;
if dis 1=O then dismed=.;
beahigh=.;
ifbea GE 24 then beahigh=l;
else ifbea LT 24 then beahigh=O;
ifbeal=O then beahigh=.;
beamed=.;
ifbea GE 19 and bea LT 24 then beamed=l;
else ifbea GE 24 or bea LT 19 then beamed=O;
ifbeal=O then beamed=.;
ceahigh=.;
if cea GE 30 then ceahigh= 1;
else if cea LT 30 then ceahigh=O;
ifceal=O then ceahigh=.;
ceamed=.;
if cea GE 24 and cea LT 30 then ceamed=l;
else if cea GE 31 or cea LT 24 then ceamed=O;
if cea 1=O then ceamed=.;
proc format ;
value adherence l = 'adherent'
O= 'nonadherent';
proc univariate normal plot;
var qil qi3 qi4 qi5 qi6 qi7 qi18a qi19
qi24 qi29 qi31 ;
proc freq;
tables totcomp qil qi2 qi3 qi4 qi5 qi6 qi7 qi18a qi19
qi24 qi29 qi31 ssshigh sssmed;
format totcomp adherence. ;
proc logistic descending;
model totcomp= ssshigh sssmed qil gender qi3 qi4 qi5 qi6 qi7 qi18a qi19
qi24 qi29 qi31 / ctable pprob= (0 to 1 by .1) lackfit risklimits; run;
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/*SAS PROGRAM TO DICHOTOMIZE PATIENTS ON PROTEASE INHIBITOR
DRUGS AS BEING ADHERENT OR NON ADHERENT
BASED ON MEDICATION ADHERENCE SCALE.*/
options nocenter linesize=72;
libname saurabh 'c:\Docwnents and Settings\Erabus\DESKTOP\saurabh';
data saurabh3;
set saurabh.hivsurv;
if qiilx4=0 then qiilx4=99;
if qiilx5=0 then qiilx5=99;
ifqiilx6=0 then qiilx6=99;
ifqiilx7=0 then qiilx7=99;
if qiilx8=0 then qiilx8=99;
if qii 1x9=0 then qii 1x9=99;
if qii2x4=0 then qii2x4=99;
if qii2x5=0 then qii2x5=99;
if qii2x6=0 then qii2x6=99;
if qii2x7=0 then qii2x7=99;
if qii2x8=0 then qii2x8=99;
if qii2x9=0 then qii2x9=99;
if qii3x4=0 then qii3x4=99;
if qii3x5=0 then qii3x5=99;
if qii3x6=0 then qii3x6=99;
if qii3x7=0 then qii3x7=99;
if qii3x8=0 then qii3x8=99;
if qii3x9=0 then qii3x9=99;
maslx= qii lx4+qiilx5+qiilx6+qii lx7+qii lx8+qii lx9;
ifmaslx GE 109 then masl=O;
mas2x= qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9;
ifmas2x GE 109 then mas2=0;
mas3x= qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9;
ifmas3x GE 109 then mas3=0;
data saurabh5;
set saurabh3;
if qiilx4=99 then qiilx4=0;
if qiilx5=99 then qiilx5=0;
ifqiilx6=99
ifqiilx7=99
if qiilx8=99
ifqiilx9=99

then qiilx6=0;
then qiilx7=0;
then qiilx8=0;
then qiilx9=0;

mas 1=qii1x4+qii1x5+qii1x6+qii1x7+qii1x8+qii1 x9;
ifmaslx=O then masl=O;
if qii2x4=99 then qii2x4=0;
if qii2x5=99 then qii2x5=0;
if qii2x6=99 then qii2x6=0;
if qii2x7=99 then qii2x7=0;
if qii2x8=99 then qii2x8=0;
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if qii2x9=99 then qii2x9=0;
(

mas2=qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9;
if mas2x=O then mas2=0;
if qii3x4=99 then qii3x4=0;
if qii3x5=99 then qii3x5=0;
if qii3x6=99 then qii3x6=0;
if qii3x7=99 then qii3x7=0 ;
if qii3x8=99 then qii3x8=0;
if qii3x9=99 then qii3x9=0;
mas3 =qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9;
ifmas3x=O then mas3=0;
if qiilx= 'bact1im' then masl =O;
if qii Ix= 'acyclovir' then mas I =O;
if qiilx= 'pentam.idine' then masl =O;
if qiilx= 'zoloft' then masl=O;
ifqiilx= '3tc' then masl=O;
if qiilx= 'azt' then masl=O;
ifqiilx= 'd4t' then masl=O;
ifqiilx= 'ddi' then masl =O;
if qiilx= 'ddc' then masl=O;
ifqiilx= 'epivir' then masl =O;
if qiilx= 'zerit' then masl =O;
if qii2x= 'bactrim' then mas2=0;
if qii2x= 'dapsone' then mas2=0;
if qii2x= 'leucovorin' then mas2=0;
if qii2x= 'ms contin' then mas2=0;
if qii2x= 'theodur' then mas2=0;
if qii2x= 'Jtc' then mas2=0;
if qii2x= 'azt' then mas2=0;
if qii2x= 'd4t' then mas2=0;
if qii2x= 'ddc' then mas2=0;
if qiilx= 'ddi' then masl =O;
if qiilx= 'epivir' then masl =O;
if qiilx= 'zerit' then masl =O;
if qii3x= 'acyclovir' then mas3=0;
if qii3x= 'bactrim' then mas3 =0;
if qii3x= 'biaxin' then mas3=0;
if qii3x= 'clotrimazole' then mas3=0;
if qii3x= 'compazine' then mas3=0;
if qii3x= 'dapsone' then mas3=0;
if qii3x= 'diltiazem' then mas3=0;
if qii3x= 'fluconazole' then mas3=0;
if qii3x= 'mellaril' then mas3=0;
if qii3 x= 'minocycline' then mas3=0;
if qii3x= 'motrin' then mas3=0;
if qii3x= 'oxandrin' then mas3=0;
if qii3x= 'vasotec' then mas3=0;
if qii3x= 'zantac' then mas3=0;
if qii3x= 'zovirax' then mas3=0;
if qii3x= '3tc' then mas3=0;
if qii3x= 'azt' then mas3=0;
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(

if qii3x= 'd4t' then mas3=0;
if qii3x= 'epivir' then mas3=0;
totmas=mas 1+mas2+mas3;
ifmasl NE 0 and mas2 NE 0 and mas3 NE 0 then totmas= totmas/3;
ifmasl NE 0 and mas2= 0 and mas3 NE 0 then totmas= totmas/2;
ifmasl=O and mas2 NE 0 and mas3 NE 0 then totmas= totmas/2;
ifmasl NE 0 and mas2 NE 0 and mas3=0 then totmas= totmas/2;
if mas 1 NE 0 and mas2=0 and mas3=0 then totmas=totmas;
if mas 1=O and mas2 NE 0 and mas3=0 then totrnas=totmas;
ifmasl=O and mas2=0 and mas3 NE 0 then totmas=totmas;
if totmas LT 6 then delete;
totmas 1=12-totmas;
iftotmasl = 6 then totmasl =1;
else iftotrnasl LE 6 then totmasl =O;
ifqvil=O then qvi1=99;
if qvi2=0 then qvi2=99;
if qvi3=0 then qvi3=99;
if qvi4=0 then qvi4=99;
if qvi5=0 then qvi5=99;
if qvi6=0 then qvi6=99;
if qvi7=0 then qvi7=99;
if qvi8=0 then qvi8=99;
if qvi9=0 then qvi9=99;
if qvi 1O=O then qvi 10=99;
if qvi 11 =O then qvi 11 =99;
ifqvi12=0 then qvi12=99;
if qvi 13=0 then qvi 13=99;
if qvi14=0 then qvi14=99;
if qvi 15=0 then qvi 15=99;
if qvi 16=0 then qvi 16=99;
if qvil 7=0 then qvi 17=99;
if qvi 18=0 then qvi 18=99;
if qvi 19=0 then qvi 19=99;
if qvi20=0 then qvi20=99;
if qvi21 =O then qvi21 =99;
if qvi22=0 then qvi22=99;
if qvi23=0 then qvi23=99;
if qvi24=0 then qvi24=99;
if qvi25=0 then qvi25=99;
if qvi26=0 then qvi26=99;
if qvi27=0 then qvi27=99;
if qvi28=0 then qvi28=99;
if qvi29=0 then qvi29=99;
if qvi30=0 then qvi30=99;
if qvi31 =O then qvi31 =99;
if qvi32=0 then qvi32=99;
if qvi33=0 then qvi33=99;
if qvi34=0 then qvi34=99;
if qvi35=0 then qvi35=99;
if qvi36=0 then qvi36=99;
if qvi37=0 then qvi37=99;
if qvi38=0 then qvi38=99;
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if qvi39=0
if qvi40=0
if qvi4 l =O
if qvi42=0
if qvi43=0
if qvi44=0
if qvi45=0
if qvi46=0
if qvi47=0
if qvi48=0
if qvi49=0
if qvi50=0

then qvi39=99;
then qvi40=99;
then qvi4 l =99;
then qvi42=99;
then qvi43=99;
then qvi44=99;
then qvi45=99;
then qvi46=99;
then qvi47=99;
then qvi48=99;
then qvi49=99;
then qvi50=99;

sss 1=qvi4+qvi34+qvi22+qvi20+qvil6+qvi49+qvi l 3+qvi3 l +qvi6+qvi l 9+qvi 1;
dis 1=qvi40+qvi30+qvi33+qvi9+qvi1O+qvi11+qvi50+qvi37+qvi l 5+qvi32+qvi48+qvi52;
fop 1=qvi26+qvi27+qvil7+qvi4 l +qvi2 l +qvi28+qvi l 4+qvi4 7;
bea 1=qvi29+qvi23+qvi24+qvi35+qvi39+qvil8+qvi5+qvi3+qvi25;
cea 1=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi5l+qvi12;
ifsssl GT 149 then sssl=O;
ifdisl GT 154 then disl=O;
iffopl GT 134 then fopl=O;
ifbeal GT 139 then beal=O;
ifceal GT 139 then ceal=O;
run;
data saurabh7;
set saurabh5;

if qvil =99 then qvi 1=O;
if qvi2=99 then qvi2=0;
if qvi3=99 then qvi3=0;
if qvi4=99 then qvi4=0;
if qvi5=99 then qvi5=0;
if qvi6=99 then qvi6=0;
if qvi7=99 then qvi7=0;
if qvi8=99 then qvi8=0;
if qvi9=99 then qvi9=0;
if qvi 10=99 then qvi 1O=O;
if qvil 1=99 then qvil 1=O;
if qvi12=99 then qvil2=0;
if qvi 13=99 then qvi 13=0;
if qvil4=99 then qvil4=0;
if qvi15=99 then qvil5=0;
if qvi 16=99 then qvi 16=0;
if qvil 7=99 then qvil 7=0;
if qvi 18=99 then qvi 18=0;
if qvi 19=99 then qvi 19=0;
if qvi20=99 then qvi20=0;
if qvi21 =99 then qvi2 l =O;
if qvi22=99 then qvi22=0;
if qvi23=99 then qvi23=0;
if qvi24=99 then qvi24=0;
if qvi25=99 then qvi25=0;
if qvi26=99 then qvi26=0;
if qvi27=99 then qvi27=0;
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if qvi28=99 then qvi28=0;
if qvi29=99 then qvi29=0;
if qvi30=99 then qvi30=0;
if qvi31 =99 then qvi31 =O;
if qvi32=99 then qvi32=0;
if qvi33=99 then qvi33=0;
if qvi34=99 then qvi34=0;
if qvi35=99 then qvi35=0;
if qvi36=99 then qvi36=0;
if qvi37=99 then qvi37=0;
if qvi38=99 then qvi38=0;
if qvi39=99 then qvi39=0;
if qvi40=99 then qvi40=0;
if qvi41 =99 then qvi41 =O;
if qvi42=99 then qvi42=0;
if qvi43=99 then qvi43=0;
if qvi44=99 then qvi44=0;
if qvi45=99 then qvi45=0;
if qvi46=99 then qvi46=0;
if qvi47=99 then qvi47=0;
if qvi48=99 then qvi48=0;
if qvi49=99 then qvi49=0;
if qvi50=99 then qvi50=0;
sss=qvi4+qvi34+qvi22+qvi20+qvi 16+qvi49+qvi 13+qvi31+qvi6+qvi19+qvi 1;
dis=qvi40+qvi30+qvi33+qvi9+qvi 1O+qvi11+qvi50+qvi37+qvi15+qvi32+qvi48+qvi52;
fop=qvi26+qvi27+qvi 17+qvi41 +qvi21+qvi28+qvi14+qvi4 7;
bea=qvi2 9+qvi23+qvi24+qvi3 5+qvi39+qvi18+qvi5+qvi3+qvi25;
cea=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi51+qvi12;
if sss 1=O then sss=.;
if dis 1=O then dis=.;
if fop 1=O then fop=.;
ifbeal=O then bea=.;
ifceal=O then cea=.;
label totmasl= 'adherence to AV drugs';
label qil= 'age';
label qi2='gender';
label qi3= 'health status';
label qi4='ethnicity';
label qi5='education';
label qi6='employment';
label qi7='living arrangement';
label qil8a ='insurance';
label qi19='income';
label qi24='body pain';
label qi29='how long ago diagnosed';
label qi3 l ='t cell count';
/* new variable 'gender' created*/
gender=.;
if qi2= 'm' then gender=l;
else if qi2= 'f then gender=O;

/* variable age categorized into three catego1ies*/
if qil It 35 then qi 1=3;
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(

elseifqil ge35andqil le41 thenqil =2 ;
else ifqil ge 42 then qil=l;
/* variab le etl111icity dichotomized to whites or nou whites*/
if qi4=0 then qi4=.;
else if qi4= 1 then qi4=1;
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0;
/* variable education dichotomized*/
if qi5=0 then qi5=.;
else if qi5 It 12 then qi5= 1;
else if qi5 ge 12 then qi5=0;
/* variable employment dichotomized */
if qi6=0 then qi6=.;
else if qi6=1 or qi6=2 then qi6=0;
else if qi6=3 then qi6=1;
I* variable living ai.Tangement dichotomized */
if qi7=0 then qi7=.;
else if qi7=1 then qi7=1;
else if qi7=2 then qi7=0;

/* variable health status dichotomized */
if qi3=0 then qi3=.;
else if qi3=1 or qi3=2 or qi3=3 then qi3=0;
else if qi3=4 or qi3=5 then qi3=1;

/* variable insurance dichotomized */
if qi l 8a=O then qi l 8a=.;
if qi18a=2 then qi18a=l;
else if qil 8a=l then qi l 8a=O;
/* variable income dichotomized*/
if qil 9=0 then qil 9=.;
else if qil9=1 then qi 19=1;
else if qil9=2 or qil9=3 or qil9=4 or qil9=5 then qil9=0;
/* variable body pain dichotomized */
if qi24=0 then qi24=.;
else if qi24=1 or qi24=2 or qi24=3 then qi24=0;
else if qi24=4 or qi24=5 or qi24=6 then qi24=1;
/* variable how long ago diagnosed categorized*/
if qi29=0 then qi29=. ;
else if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=3;
else if qi29=5 then qi29=2;
else if qi29=6 then qi29=1;
I* variable T celJ count dichotomized*/
if qi3 l =O then qi3 l =.;
else ifqi31= 1 or qi31 =2 then qi31=0 ;
else if qi3 l = 3 or qi31 =4 then qi3 l =l;

sssmed=.;
if sss It 30 or sss ge 35 then sssmed= O;
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(

else if sss ge 30 and sss lt 35 then sssmed=l;
if sss 1=O then sssmed=.;
ssshigh=.;
if sss ge 35 then ssshigh=l;
else if sss It 35 then ssshigh=O;
if sss 1=O then ssshigh=.;
fophigh=.;
if fop GE 29 then fophigh=l;
else if fop LT 29 then fophigh=O;
if fop 1=O then fophigh=.;
fopmed=.;
if fop GE 23 and fop LT 29 then fopmed=l ;
else if fop GE 29 or fop LT 23 then fopmed=O;
if fop 1=O then fopmed=.;
dishigh=.;
if dis GE 39 then dishigh=l ;
else if dis LT 39 then dishigh=O;
if disl =O then dishigh=.;
dismed=.;
if dis GE 34 and dis LT 39 then dismed=l;
else if dis GE 39 or dis LT 34 then dismed=O;
if dis 1=O then dismed=.;
beahigh=.;
ifbea GE 25 then beahigh=l;
else ifbea LT 25 then beahigh=O;
ifbeal =O then beahigh=.;
beamed=.;
ifbea GE 20 and bea LT 25 then beamed=l;
else if bea GE 25 or bea LT 20 then beamed=O;
ifbeal =O then beamed=.;
ceahigh=.;
if cea GE 30 then ceahigh=l;
else ifcea LT 30 then ceahigh=O;
ifceal =O then ceahigh=.;
ceamed=.;
if cea GE 24 and cea LT 30 then ceamed=l;
else if cea GE 30 or cea LT 24 then ceamed=O;
if cea 1=O then ceamed=.;
proc format;
value adherence 1= 'adherent'
O= 'nonadherent';
proc univariate normal pl ot;
var qil qi3 qi4 qi5 qi6 qi7 qil 8a qil9
qi24 qi29 qi3 l ;
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proc freq;
tables totmasl qil qi2 qi3 qi4 qi5 qi6 qi7 qi18a qi19
qi24 qi29 qi31 ssshigh sssmed;

format totmas 1 adherence.;
proc logistic descending;
model totmasl = ssshigh sssmed qil gender qi3 qi4 qi5 qi6 qi7 qil8a qil9
qi24 qi29 qi3 l / ctable pprob= (0 to l by .1) lackfit risklinuts;
run ;
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Appendix-III- Ways of coping with HIV

Response options for the scale:
1- Never
2- Rarely
3- Occasionally
4- Often
5- Very often
Here are some ways that different people may cope with HIV and its treatment.
There are no right or wrong answer.
In the last month, HOW OFTEN did you think, feel, or do each item? (Please
circle one number for each item.
In the last month, I

1. concentrate on the next step
2. felt the only thing to do was wait
3. did something just to do something
4. talked to someone to find out more
5. criticized or lectured myself
6. tried not to close off options
7. hoped a miracle would happen
8. went along with faith
9. went on as if nothing had happened
10. tried to keep my feelings to myself
11 . looked for the silver lining; looked on the bright side
12. slept more than usual
13. looked for sympathy and understanding
14. was inspired to be creative
15. tried to forget the whole thing
16. tried to get professional help
17. changed or grew as a person in a good way
18. waited to see what would happen before acting
19. made a plan of action and followed it
20. let my feelings out somehow
21 . came out of the experience better than before
22. talked to someone who could do something
23. tried to make myself feel better by eating, drinking, smoking, or drug use
24. took a big chance and did something risky
25. tried not to act too hastly
26. found new faith
27. rediscovered what is important in life
28. changed something so thing will turn out
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29. avoided being with people
30. didn' t let it get to me; refused to think about it
31. asked a friend or relative for advise
32. kept others from knowing how bad things were
33. made light of it; refused to get too serious
34. talked to someone about how I was feeling
35. took it out on other people
36. drew on past experiences from similar situations
3 7. knew what had to be done, so increased efforts
38. refused to believe it was happening
39. came up with different solutions
40. tried to keep my feelings from interfering
41. changed something about myself
42. wished the situation would go away or be over
43. had fantasies/ wishes about how it might turn out
44. prayed
45. prepared for the worst
46. went over in my mind what I would say or do
47. though of how a person I admire would act
48. reminded myself how much worst things could be
49. tried to find out as much as I could
50. treated the illness as a challenge

(
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